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Abstract 
Background: Pharmacovigilance is an important tool not only in protecting patients from 
potentially harmful effects of medicines, but it plays a role in providing good quality of care 
and monitoring efficacy of drug products within a population. Spontaneous reporting is a 
system of reporting adverse drug reactions (ADRs) practiced worldwide as part of the WHO 
Programme for International Drug Monitoring. Unfortunately, the major drawback of this 
system is the underreporting of ADRs.  
Methodology: A cross-sectional questionnaire-based survey was conducted amongst 
pharmacists and nurses in six private hospitals in Gauteng. A pre-designed and structured 
multiple choice questionnaire containing 20 close-ended questions was used to assess 
demographics (four questions), knowledge (six questions), attitudes (five questions) and 
practices (five questions) of participants. E-mail and manual questionnaires were provided to 
target as many nurses and pharmacists as possible. Electronic responses were captured as 
they were submitted, while manual responses were collected by the principle investigator 
from a contact person identified within each hospital. The data obtained was analysed using 
appropriate statistical analysis through Microsoft Excel 2010 and Google Forms software.  
Results: A total of 233 healthcare professionals participated in the study. Although three 
quarters of participants believed ADR reporting to be important, most had received no 
previous pharmacovigilance training and did not know how to report an ADR. 87.1% of 
participants believed that all ADRs should be reported, with 75.5% of participants believing 
they would report all ADRs they encountered in the future provided they had sufficient 
training and knowledge. The major factors discouraging participants from reporting was a 
lack of awareness with respect to the process of reporting as well as a lack of access to the 
ADR reporting form.  
Conclusion: This study indicates that the majority of participants require further training 
regarding ADR reporting. Although the knowledge of most participants was acceptable, the 
transition into practice needs to be improved.  
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CHAPTER 1 
INTRODUCTION 
1.1. INTRODUCTION 
This introductory chapter describes the background to and rationale for the study. The 
primary research question as well as the aims and objectives are provided. Additionally, the 
significance of the study is discussed. Lastly, an outline of the dissertation will conclude the 
chapter.  
 
1.2. BACKGROUND AND RATIONALE 
Adverse drug reactions (ADRs) affect a number of patients worldwide, irrespective of age, 
gender, location or occupation, and can affect patients with varying magnitudes leading to 
morbidity and mortality (Pirmohamed et al, 2004). Lazarou and colleagues estimated in 1998 
that ADRs can be considered to be the 4th – 6th leading cause of death in the United States 
(Lazarou et al, 1998). It is estimated that the burden of ADRs in developing countries such 
as South Africa is even higher than in developed countries due to the high prevalence of 
self-medication, fake and unadulterated medicines, and traditional and herbal therapies 
(SPS, 2011). Additionally, diseases such as Human Immunodeficiency Virus (HIV), 
tuberculosis (TB) and malnutrition, which are highly prevalent in South Africa, are widely 
known to increase the risk of ADRs in certain populations of patients.  
 
Underreporting of ADRs is considered to be a global issue. In South Africa, where 
pharmacovigilance (PV) and other regulatory aspects of medicine use are not yet fully 
developed, ADR reporting rates are still very low. South Africa has submitted a total of 28 
609 reports to VigiBase® since an official PV system begun functioning in 1992 (Ampadu et 
al, 2016). This amounts to approximately 27 reports per million people per year. Because 
South Africa has a population of approximately 52 million, this figure is expected to be higher 
(Stats SA, 2017). 
 
Literature indicates that a lack of awareness and appreciation of the magnitude of the 
problem of ADRs and ADR underreporting, as well as misclassification of ADRs, is partially 
to blame for this epidemic. Many ADRs are considered to be preventable with more rational 
prescribing, administration and use. Frameworks for evaluating the safety of medicines in 
clinical use are vital, and therefore a functional PV system is of utmost importance (Mehta, 
2011, Dheda et al, 2013).  
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The private healthcare sector in South Africa is a seldom studied field of healthcare. Most 
studies conducted in the country tend to focus on public sector facilities and patients. Public 
sector patients make up the majority of the population (42 million people in public vs. 8.2 
million people in private) and are useful in investigating public health issues(Jobson, 2015).  
However, approximately 17% of the population are members of a private medical scheme 
and hence benefit from private sector healthcare services (Stats SA, 2017). Healthcare 
expenditure in the private sector amounted to R 151.21 billion in 2016 (CMS, 2017). Medical 
scheme benefits in 2016 for medicines amounted to approximately R 24 billion accounting 
for approximately 16% of total healthcare benefits paid (CMS, 2017). Meanwhile, only R 74 
million was allocated to medicine procurement in the public sector in 2015 (National 
Treasury, 2015). However, it is important to keep in mind that the prices of medicines 
procured in the public sector are often supplied at drastically reduced prices when compared 
to prices charged for procurement and supply in the private sector. 
 
1.3. RESEARCH QUESTION 
What are the current knowledge, attitudes and practices of nurses and pharmacists towards 
adverse drug reaction reporting in the private sector? 
 
1.4. PURPOSE OF THE STUDY 
1.4.1. Aim 
This study aimed to evaluate the knowledge, attitudes and practices of pharmacists and 
nurses in the private hospital sector towards ADR reporting. 
 
1.4.2. Objectives 
I. Assessed the knowledge of private sector HCPs regarding the ADR reporting process in 
South Africa. 
II. Assessed the attitudes of private sector HCPs towards ADR reporting and varying 
components of ADR reporting.  
III. Evaluated ADR reporting practices of private sector HCPs. 
IV. Established factors that contributed to differences in both knowledge and attitudes 
towards ADR reporting. 
V. Explored trends that interfered with effective ADR reporting.  
 
1.5. IMPORTANCE/SIGNIFICANCE OF THE STUDY 
This is the first study of its kind targeting the South African private sector specifically. Most 
PV or ADR studies in the country have thus far been focused on individual public sector 
facilities (Isah et al, 2012; Joubert& Naidoo, 2016; Mouton et al, 2015; Mouton et al, 2016; 
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Roux, 2014; Ruud et al, 2010). Although the private sector represents a minority of the 
population (approximately 17%), it cannot be neglected when reviewing current PV 
frameworks and practices. Regardless of sector of employment, health care professionals 
(HCPs) have the responsibility and duty to play an important role in the detection, 
assessment and reporting of ADRs (Khalili et al, 2012). 
 
Spontaneous and voluntary reporting is an integral component of any PV program, and is 
the cheapest and most effective method of obtaining information on ADRs. It has contributed 
significantly to the knowledge and understanding of safe and effective medicine use 
worldwide. However, due to the low reporting rate in South Africa, the understanding of the 
safety profiles of medicines are often delayed, resulting in patients often being exposed to 
medicines that are either unsafe, or that have an uncertain safety profile (Mehta, 2011).  
 
In order to improve ADR reporting rates in South Africa, an analysis of the current state of 
PV activity needs to take place. This study attempted to establish a baseline evaluation in 
order to understand whether or not HCPs are making PV a priority activity in the clinical 
management of their patients. Based on the final results of the study, recommendations will 
be made with respect to education and practices of HCPs with the aim of improving overall 
ADR reporting rates. Improved knowledge of the magnitude of the ADR problem might lead 
to better and more motivated attitudes in implementing and internalising PV in every day 
clinical practice.  
 
1.6. OUTLINE OF THE DISSERTATION 
This dissertation consists of six chapters. Chapter 1 is an introductory chapter, introducing 
the background to and rationale for the study. It also states the research question, and aims 
and objectives of the study. A brief discussion of the significance of the study is also 
included. Chapter 2 is a literature review including a discussion on the current state of PV in 
South Africa and worldwide, the incidence of and costs related to ADRs, medication errors 
as a source of ADRs and types of ADR reports. It will also discuss underreporting of ADRs 
based on available literature in both a global and local context. Chapter 3 discusses the 
methodology of the study. It elaborates on the study design population, development of the 
questionnaire used in the study, data collection and analysis, and reliability and validity. 
Ethical considerations and limitations of the study are also included. Chapter 4 presents the 
results of the study in both narrative and descriptive format, followed by Chapter 5 that 
discusses the results presented in the previous chapter. Chapter 6 concludes the 
dissertation by including recommendations for future studies and a conclusion. Figure 1.1 
provides a short illustration of the layout of this dissertation.  
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Figure 1.1. Layout of the dissertation 
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CHAPTER 2 
LITERATURE REVIEW 
2.1. INTRODUCTION 
In this chapter, an overview of the published literature is provided. The chapter begins with a 
background into PV, as well as a discussion about PV within a South African context. The 
incidence of ADRs, ADR related costs, and the role of medication errors with respect to 
ADRs is also described. A brief discussion of the type of ADR reports is also included. 
Finally, a summary of underreporting in a global context is provided, including an overview of 
the literature regarding the knowledge, attitudes and practices of HCPs in various settings. 
2.2. PHARMACOVIGILANCE 
Pharmacovigilance (PV) is defined as the “science and activities relating to the detection, 
assessment, understanding and prevention of adverse drug effects or any other drug-related 
problem” (WHO, 2002). This definition has since been extended to include all aspects of 
medicine development, manufacturing, registration, warehousing, logistics, prescribing, 
dispensing, use and destruction of expired stock, thereby spanning the complete product life 
cycle.  
2.2.1. PHARMACOVIGILANCE: A GLOBAL ISSUE 
In 1968, after the global thalidomide disaster, the World Health Organization (WHO) sought 
to establish an international collaborative effort with regards to medicines’ safety through the 
collection of worldwide ADR data (Pirmohamed et al, 2007). This effort was named “The 
WHO Programme for International Drug Monitoring (PIDM)”, and in 1978, the Uppsala 
Monitoring Centre (UMC) was established as the operational body responsible for carrying 
out the functions of global ADR collation and monitoring (Pirmohamed et al, 2007). The 
WHO PIDM launched VigiBase® in 2001. It is the largest database of its kind, containing 
over 15 million individual case safety reports (ICSRs) of suspected adverse drug reactions. 
In 2015, the WHO launched VigiAccess™ - a web application that allows anybody to access 
the ADR information stored in VigiBase®, and is aimed at encouraging the reporting of 
ADRs.  
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Figure 2.1: Minimum Requirements for a Functional National Pharmacovigilance 
System (WHO, 2010) 
 
There are 127 countries that have joined the WHO PIDM, with 28 additional countries having 
associate membership. These associate members are still considered to be in the early 
stages of establishing their PV systems. An analysis conducted by Aagard and colleagues of 
the WHO PIDM data concluded that high-income countries are more likely than low-income 
countries to have a larger number of reports in VigiBase® (Table 2.1).They concluded that 
this was as expected as the majority of these high income countries have had established 
PV systems for a long time (most since 1968) (Aagard et al, 2012). Even for medicines that 
have a higher prevalence of use in lower income countries, such as anti-malarials, reporting 
rates for these medicines were still seen to be higher in higher income countries (Kuemmerle 
et al 2011) 
Table 2.1: Comparitive rankings of selected PIDM affiliated countries according to 
total number of ADR reports submitted to VigiBase® during 2000 – 2009 (Aagaard et 
al, 2012).  
Country Year of affiliation Number of ADR 
reports 
Reporting rate per 
million people per 
year 
United States 1968 406 274 132 
United Kingdom 1968 142 555 233 
Italy 1975 37 681 65 
A national pharmacovigilance center with designated staff (at least one full time), stable basic funding, 
clear mandates, well defined structures and roles and collaborating with the WHO Programme for 
International Drug Monitoring
The existence of a national spontaneous reporting system with a national 
individual case safety report (ICSR) form, i.e. an ADR reporting form
A national database or system for collating and managing ADR reports
A national ADR or pharmacovigilance advisory committee able to provide technical assistance on 
causality assessment, risk assessment, risk management, case investigation and, where necessary, 
crisis management including crisis communication
A clear communication strategy for routine communication and crises 
communication
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Sweden 1968 30 819 333 
Japan 1972 17 782 14 
Cuba 1994 29 932 261 
Mexico 1999 9 573 9 
Chile 1996 6 313 38 
South Africa 1992 5 518 11 
Greece 1990 1 734 16 
Ghana 2001 501 2 
India 1998 362 <1 
Russia 1998 165 <1 
Zimbabwe 1998 57 1 
 
2.2.2.  PHARMACOVIGILANCE IN SOUTH AFRICA 
Pharmacovigilance in Africa is still largely considered to be in its infancy. Improving access 
to life saving medicines took precedence over PV in low to middle income countries, 
especially in most African countries, before the availability of global funding improved 
accessibility to these medicines. This improved access increased the risk of treatment-
related adverse effects, especially in communities with limited education and few trained 
healthcare professionals (Olsson et al, 2015). However, with the emergence of a larger 
middle class that are able to pay for their medications, particularly for non-communicable 
ailments such as hypertension, national development programs shifted their focus towards 
the establishment of safety and quality surveillance systems for these medicines (Ampadu et 
al, 2016). 
In 1992, South Africa met the minimum requirements to become the first African member 
state of this collective (see Figure 2.1) (Mehta, 2014). Pharmacovigilance in South Africa is a 
responsibility shared with the medicine regulatory authority, public health programmes, the 
pharmaceutical industry and the essential drugs program (EDP). The establishment of the 
National Adverse Drug Event Monitoring Centre (NADEMC) in Cape Town in 1987 by the 
South African National Department of Health Medicines Regulatory Authority (MRA) is 
acknowledged as the official start of pharmacovigilance in South Africa.   
As of 2015, there are 35 African countries actively involved in the WHO PIDM. Together, 
they have submitted 103 449 ADR reports to VigiBase®, the WHO’s global Individual Case 
Safety Report (ICSR) database (Ampadu et al, 2016). Table 2.2 is sourced from Ampadu 
and colleagues research in 2015 and depicts South Africa’s standing with regard to ICSRs 
submitted to VigiBase® within an African context. 
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Within a more global context, South Africa seems to lag behind. Although it is difficult to find 
literature comparing total number of reports submitted since affiliation to the PIDM, over a 
ten year period (2000 – 2009) South Africa ranked 23rd behind countries such as the United 
States, Sweden, Japan, Cuba, Mexico, and Thailand (Table 2.1) (Aagaard et al, 2012).  
Table 2.2: African countries’ participation in the WHO PIDM (Ampadu et al, 2016) 
Country Year of 
joining 
No. Of ICSRs to 
2015 
No of ICSRs per 
million person 
years* 
Angola 2013 239 5.48 
Benin 2011 29 0.71 
Botswana 2009 103 8.60 
Burkina Faso 2010 76 0.92 
Cameroon 2010 46 0.42 
Cape Verde 2012 247 165.67 
Congo, the Democratic Republic of 2010 5 558 16.90 
Côte d’Ivoire 2010 28 0.28 
Egypt 2002 8474 8.62 
Eritrea 2012 1 982 104.31 
Ethiopia 2008 803 1.28 
Ghana 2001 2 900 9.07 
Guinea 2013 31 1.30 
Kenya 2010 8 440 39.07 
Liberia 2013 42 4.83 
Madagascar 2009 1 087 8.23 
Mali 2011 80 1.33 
Mauritius 2014 39 31.22 
Morocco 1992 17 231 25.38 
Mozambique 2005 797 3.36 
Namibia 209 1 604 119.25 
Niger 2012 39 0.72 
Nigeria 2005 10 590 6.70 
Rwanda 2013 29 1.21 
Senegal 2009 181 2.44 
Sierra Leone 2008 1 272 30.97 
South Africa 1992 28 609 27.22 
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Sudan 2009 38 0.20 
Swaziland 2015 27 19.02 
Tanzania, United Republic of 1993 1 360 1.68 
Togo 2008 311 6.86 
Tunisia 1993 6 990 32.14 
Uganda 2008 1 871 7.59 
Zambia 2010 218 3.09 
Zimbabwe 1998 2 155 9.77 
*Data from VigiBase® to 30 September 2015. Cumulative population to 2014 was used as 
2015 data were not yet available. 
 
While South Africa is leading African pharmacovigilance with the greatest number of total 
reports submitted since PIMD affiliation, the number is still low when considering the 
population size. With an average number of 27 reports per million people per year, 
considering that 7.03 million people are currently living with HIV, 454 000 living with TB (as 
at 2015), as well as a high and increasing prevalence of non-communicable diseases, one 
would expect the figures for South Africa to be higher (Stats SA, 2016; WHO, 2015). 
2.2.3. SOUTH AFRICAN PHARMACOVIGILANCE STRUCTURES 
Guideline 2.3.3. Reporting of Post-Marketing Adverse Drug Reactions to Human Medicinal 
Products in South Africa (December, 2015), published by the MCC, places the responsibility 
of ADR reporting on the holders of the certificate of registration of medicines. It makes no 
provision to place responsibility on health care professionals (such as doctors, nurses or 
pharmacists) to report ADRs, despite these professionals being the most likely point of first 
contact. Although HCPs are encouraged and professionally obliged to report ADRs, how 
much information is gathered, and consequently reported, is dependent on the awareness 
and assertiveness of the health care professional (Pimpalkhute et al. 2012). 
Currently, there are a number of PV systems in South Africa. PV is a mandated function of 
the MCC and they are responsible for the regulatory aspects of PV, i.e. signal detection, 
ensuring provision of safe, effective and quality medicines, post marketing surveillance, 
instituting appropriate remedial action, and establishing the risk-benefit profile of all 
registered medical products (Maigetter et al, 2015). The other PV system is that of the 
National Pharmacovigilance Center (NPC), which is responsible for coordinating PV in public 
health programmes, particularly at Primary Health Care (PHC) level. This decentralization 
aims to increase the interest of PHC workers with respect to medicines and medicine safety.  
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In addition to the MCC and the NPC, there are a number of separate entities such as the 
Adverse Event Following Immunization System, the Operational Plan for Comprehensive 
HIV/AIDS Care, as well as non-governmental organizations such as the Wits Health 
Consortium, that have developed their own pharmacovigilance programmes that do not 
always feed into the national NADEMC system (Essack et al, 2011). Although the MCC is 
responsible for the management of these systems, there is no formal relationship between 
the MCC and other pharmacovigilance centers, nor is there any system of peer review of the 
responsible units (Essack et al, 2011). 
The current PV framework in South Africa is complex and convoluted due to the many 
possible arms of reporting, altering the direction of reporting and creating uncertainty for 
health care professionals. Although a PV framework exists for reporting, the communication 
on where the report should go is unclear. The trend is that data is often not fed to a national 
system, or not being fed centrally, which is evident from fewer generated reports (Maigetter 
et al, 2015).  Without a full understanding of the flow of reporting, practitioners may fail to 
see why reporting ADRs is worth the time invested. The lack of awareness regarding the 
process of reporting to a national ADR reporting system is cited as a common barrier to 
reporting (Suyagh et al, 2014). 
2.2.4. SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY (SAHPRA) 
In 2015, the Medicines and Related Substances Act Amendment Act, 72 of 2008 was 
passed and made provision for the establishment of a new medicines regulatory authority. 
This new body was dubbed the South African Health Products Regulatory Authority 
(SAHPRA) and its board was announced in October 2017. SAHPRA intends to eventually 
replace the MCC as the medicine regulatory authority in South Africa. It has been described 
as being based on a similar model as the Food and Drug Administration (FDA) in the United 
States in that it is an independent body, falling outside of the South African Department of 
Health and will therefore not be at risk of political interference. As a more stringent and 
independent authority, SAHPRA hopes to improve pharmacovigilance monitoring in the 
country. So far, it aims to make the process of registration more transparent, i.e. different 
stages of registration will be more readily accessible to the South African public (Rogers and 
Langbridge, 2016).  
One of the biggest improvements to SAHPRA, when compared to the MCC, is that it will also 
be responsible for the registration and regulation of medical devices as well as more 
stringent regulation of complementary medicines. Complementary medicines have been 
called up for registration in 2014 and have until 2019 to be registered with the regulatory 
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authority. Companies that manufacture medical devices had until August 2017 to register 
themselves, while medical devices themselves will be called up in 2018 (Goemans, 2017).  
As a result of all the above improvements and upgrades, SAHPRA will aim to increase 
pharmacovigilance monitoring in South Africa within a space of ethics versus science. By 
having already aligned itself with agencies such as the FDA, European Medicines Agency 
(EMA) and the International Coalition of Medicines Regulatory Authorities (ICMRA), 
SAHPRA will hopefully be able to provide South Africa with an improved ADR reporting and 
monitoring system in line with more developed countries (Spotlight, 2016).  
2.3. ADVERSE DRUG REACTIONS 
An adverse drug reaction (ADR) is defined by the Medicine Control Council (MCC) as “a 
response to a medicine in humans or animals, which is noxious and unintended, including 
lack of efficacy, and which occurs at any dosage and can also result from overdose, misuse 
or abuse of a medicine” (MCC, 2014). The difference between an ADR and an adverse drug 
event (ADE) is aptly summarised as an ADE being used to refer harm incurred by 
appropriate or inappropriate use of a drug, whereas an ADR is a direct subset of these 
events with harm being caused by use of a drug under appropriate circumstances and at 
normal doses (Nebeker et al, 2004). ADEs may include medication errors (during 
prescribing, dispensing or administration), non-adherence or incorrect dosages (Nebeker et 
al, 2004). According to the definition provided by the MCC, both ADEs and ADRs are 
required to be reported. There are a number of different types of reports currently acceptable 
in the South African PV framework, broadly divided into voluntary and non-voluntary reports, 
and will be discussed in more detail later in this chapter. 
2.3.1. CLASSIFICATION OF ADVERSE DRUG REACTIONS 
ADRs can be classified in a number of different ways: 
- Onset of event: Acute (<60 minutes); Sub-acute (1 – 24 hours); Latent (>2 days) 
- Type of reaction: Type A, B, C, D, E, F, G, H, U (see Table 2.3 below) 
- Severity: Minor, Moderate, Severe, Fatal 
Table 2.3. Wills and Brown ADR Classification (Angeline & Perumaloo, 2015)  
Type Description Examples 
A (Augmented) A dose dependent, 
predictable reaction based 
on the pharmacology of the 
Beta-blockers  bradycardia 
Warfarin  bleeding 
23 | P a g e  
 
drug. Usually alleviated with 
a dose reduction 
B (Bizarre) Not dose dependent and 
cannot be predicted based 
on the pharmacology of the 
drug. Predisposition is 
usually dependent on 
individual patient factors 
Penicillin  anaphylaxis 
Anticonvulsant  
hypersensitivity  
C (Chemical) Biological or biochemical 
reactions based on the 
chemical structure of the 
drug/metabolite 
Paracetamol  
hepatotoxicity  
Paclitaxel  extravasation 
D (Delayed) Occur after many years of 
drug exposure – may be due 
to an accumulation of 
metabolites in the body 
Chemotherapy  secondary 
tumours 
Antipsychotics  tardive 
dyskinesia 
E (Exit) Occur on abrupt withdrawal 
of a drug 
Phenytoin  seizures 
Corticosteroids  
adrenocortical insufficiency  
F (Familial) Occur only in patients with 
genetic predispositions 
Primaquin haemolytic 
anaemia in G6PD deficiency 
G (Genotoxicity) Irreversible genetic damage  Thalidomide  teratogenicity  
ACE-Inhibitors  hypoplasia 
of organs 
H (Hypersensitivity) An immune mediated 
response. Can be classified 
into Type I (immediate, 
anaphylactic); Type II 
(Cytotoxic antibody); Type III 
(serum sickness); Type IV 
(delayed hypersensitivity)  
Penicillin  anaphylaxis 
Methyldopa  haemolytic 
anaemia  
U (Unclassified) Reactions in which the 
mechanism is unclear  
Simvastatin  taste 
disturbances  
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2.4. INCIDENCE OF ADVERSE DRUG REACTIONS 
2.4.1. GLOBAL AND LOCAL FIGURES  
ADRs affect a number of patients worldwide, irrespective of age, gender, location or 
occupation, and can affect patients with varying magnitudes leading to morbidity and 
mortality (Pirmohamed et al, 2004). Lazarou and colleagues estimated in 1998 that ADRs 
can be considered to be the 4th – 6th leading cause of death in the United States, with the 
incidence having remained stable over the previous 30 year period (Lazarou et al, 1998). 
This placed ADRs as a cause of death ahead of diseases such as pneumonia and diabetes 
(Lazarou et al, 1998). Additionally, a meta-analysis conducted by Wiffen of 69 prospective 
and retrospective studies worldwide involving 419 000 patients concluded that ADRs were 
responsible for approximately 6.7% of all hospitalizations (Wiffen, 2002). It is estimated that 
the burden of ADRs in developing countries such as South Africa is even higher than in 
developed countries due to the high prevalence of self-medication, fake and unadulterated 
medicines, and traditional and herbal therapies (SPS, 2011). 
A recent study conducted in four hospitals in South Africa by Mouton and colleagues found 
that 1 in 12 hospital admissions were due to an ADR (Mouton et al, 2016). 58% of these 
patients were taking more than 5 drugs at time of admission (range 1 – 17 drugs) and 39% 
of admitted patients were HIV positive (Mouton et al, 2016). South African patients tend to 
provide the perfect landscape for ADRs as a result of the cocktail of medications prescribed 
for the treatment of HIV, TB and non-communicable diseases (Mehta, 2011).  Additionally, 
herbal and traditional medicines are a popular choice for many South Africans due to their 
low cost and free availability. The market for these medicines is estimated at approximately 
R 3 billion with at least 27 million people consuming herbal or traditional medicines annually 
(Essack et al, 2011; BMI, 2010). The use of herbal and traditional medicines raises concerns 
about safety as their contents are often not well known and may consist of potentially 
harmful ingredients (Isah et al, 2012). 
2.4.2. REASONS FOR HIGH INCIDENCE  
Harmful self-medication practices are a cause for concern with respect to ADRs. Easily 
accessible over-the-counter (OTC) medicines, as well as prescription-only drugs, are often 
procured from uneducated and uninformed persons in the informal sector (Isah et al, 2012). 
Additionally, the use of “gift” medicines from friends and family as well as the sharing of 
medicines without appropriate medical supervision often leads to harm, the magnitude of 
which is not yet quantified (Isah et al, 2012).  
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Not all effects of medicines, whether beneficial or harmful, can be identified during clinical 
trials and other pre-marketing phases of drug development. This is usually due to the small 
number of patients, short term use, co-morbidities, pharmacogenetics with respect to both 
heterogenous and homogenous populations, and concomitant use of other medications, 
foods, and herbal remedies (Smith et al, 2013; Wiktorowicz et al, 2012). Pharmacogenetics 
plays a big role in determining the beneficial or adverse response to a medicine. Data 
emerging from clinical trials is based on a small, often homogenous population making it 
difficult to extrapolate safety data to a more genetically diverse population, such as the one 
found in South Africa. For example, McDowell and colleagues performed a meta-analysis on 
the link between ethnicity and adverse drug reactions to cardiovascular drugs. They found a 
previously unpublished threefold increase in the risk of angioedema in black patients taking 
angiotension converting enzyme inhibitors (ACE-Is), when compared to non-black patients 
(McDowell et al, 2006). ACE-Is are often first-line therapy for the treatment of hypertension 
in South Africa and therefore a need to monitor outcomes, including ADRs, should be a 
priority activity. 
There have been several studies and meta-analyses such as Mouton and colleagues all 
over the world in attempts to quantify the impact of ADRs on healthcare in both an individual 
and societal capacity. Literature both confirms that ADRs are a global health problem and 
suggests that more care needs to be taken in the avoidance of ADRs. 
 
2.5. MEDICATION ERRORS 
2.5.1. DEFINITION  
Because the definitions of PV and ADRs include the use of medicines in a prescribing, 
dispensing and administration capacity, medication errors in the context of 
pharmacovigilance need to be addressed. The National Coordinating Council for Medication 
Error Reporting and Prevention (NCC MERP) is an international body that aims to maximise 
the safe use of medicines and increase awareness of medication errors in order to prevent 
them occurring. The NCC MERP defines a medication error as, “…any preventable event 
that may cause or lead to inappropriate medication use or patient harm while the 
medication is in the control of the health care professional, patient, or consumer. Such 
events may be related to professional practice, health care products, procedures, and 
systems, including prescribing, order communication, product labeling, packaging, and 
nomenclature, compounding, dispensing, distribution, administration, education, 
monitoring, and use." 
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2.5.2. CLASSIFICATION OF MEDICATION ERRORS 
Medication errors can be classified according to the way in which the error occurred. This is 
important in the context of PV as it can emphasise the need for vigilant and competent 
HCPs, as well as to distinguish whether an adverse effect of a medicine is due to a 
medication error or as a result of the drug itself. 
Figure 2.2. Classification of Medication Errors (adapted from Truter et al, 2017)   
 
2.5.3. CATEGORISATION OF MEDICATION ERRORS 
Medication errors are categorised according to their potential to cause harm to the patient 
and the extent of potential harm that can be caused. The information obtained from 
classifying a medication error allows the HCPs caring for the patient to formulate the best 
management plan. 
Table 2.4. Categories of Medication Error (Agency for Healthcare Research and 
Quality, 2012) 
Category Description Example 
A No error or potential to cause 
error 
N/A 
B Error that did not reach the 
patient 
N/A 
C Error that reached the patient Multivitamin not prescribed 
•Incorrect method of reconsitution or dilution
•Breaking/crushing of tablets that are not supposed to be 
broken/crushed
Inappropriate 
preparation of medicine
•Over- or underdose prescribed or administered (based on 
<10% or >10% appropriate dose for patient weight)Incorrect dose
•Medicine administered for a longer or shorter time than intended or 
prescribed
•Medicine administered at incorrect intervals (i.e. daily dose instead of 
three times daily)
Incorrect duration or 
frequency
•Medicine administered that was not prescribed - either due to 
misreading of precription or medicine administered to the 
wrong patient
Incorrect medication
•Medicine labelled incorrectly
•Can be either after reconstitution where date and volume of 
reconsitutuion not indicated
•Medicine labelled with incorrect instructions for use 
Mislabelling
•Failure to administer a prescribed medicineOmission
•Error occured during prescribing of medicine
•Can involve name and dosage of medicine, route of aministration, 
frequency or duration of treatment
Prescribing error
27 | P a g e  
 
but unlikely to cause harm 
(including omissions) 
but still administered 
D Error that reached the patient 
and could have necessitated 
monitoring and/or 
intervention to prevent harm 
Regular release metoprolol 
was prescribed but extended 
release was administered 
E Error that could have caused 
temporary harm 
Blood pressure medication 
was accidently not 
prescribed and therefore not 
administered 
F Error that could have caused 
temporary harm requiring 
hospitilisation 
Warfarin administered daily 
instead of every alternate 
day 
G Error that could have 
resulted in permanent harm 
Immunosuppressant 
medication unintentionally 
prescribed and administered 
at a quarter of the required 
dose 
H Error that could have 
necessitated intervention to 
sustain life 
Anticonvulsant therapy that 
was accidently omitted 
I Error that could have 
resulted in death 
Beta-blocker not prescribed 
post-operatively  
 
2.5.4. ADVERSE DRUG REACTIONS AS A RESULT OF MEDICATION ERRORS 
The NCC MERP has published a list of “dangerous abbreviations” to be aware of during the 
prescribing, dispensing and administration phases of drug use in order to minimise 
medication errors and medication error-related ADRs (Table 2.5). 
Table 2.5.Examples of Dangerous Abbreviations (NCC MERP, 2017) 
Abbreviation Intended Meaning Common Error 
U Units Mistaken as a zero or a four (4) resulting in 
overdose. Also mistaken for "cc" (cubic 
centimeters) when poorly written 
µg Micrograms Mistaken for "mg" (milligrams) resulting in an 
overdose 
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SC or SQ Subcutaneous Mistaken as "SL" (sublingual) when poorly written 
cc Cubic centimeters 
 
Mistaken as "U" (units) when poorly written. 
AU, AS, AD Latin abbreviation for both ears; 
left ear; right ear 
Misinterpreted as the Latin abbreviation "OU" 
(both eyes); "OS" (left eye); "OD" (right eye) 
IU International Unit Mistaken as IV (intravenous) or 10(ten) 
MS, MSO4, 
MgSO4 
Confused for one another Can mean morphine sulfate or magnesium 
sulfate 
 
In order to assist HCPs in determining whether an ADR was caused by a medication error or 
is in fact a result of the drug itself, the NCC MERP has also published an algorithm to assist 
with this determination. Figure 2.3 is adapted from the adverse drug event algorithm 
published by the NCC MERP. 
Figure 2.3. Adverse Drug Reaction Algorithm (adapted from NCC MERP) 
 
Evans and colleagues published a study in 2006 where they found that 80.9% of doctors in 
their study thought they should always report when a patient receives the wrong treatment. 
Y
Y
Y
N
Y
N
Y
N
N
Y
Y
Patient 
experiencing harm 
cause by 
medication use 
ADR previously
occured with use of 
this  drug or similar 
drug?
Previous ADR known 
or reasonably 
knowable by 
prescriber?
Potential benefit of 
us ing drug 
outweighs potential 
harm of ADR?
Drug, dose, frequency, 
route of administration 
prescribed 
appropriately?
Preventable 
ADR (harm due 
to error) 
Drug prepared/ 
dispensed 
correctly?
Drug 
administered 
correctly?
Drug effect 
monitored 
appropriately?
Non-preventable 
ADR (harm not
due to error) 
N
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However, only 57.3% believed they should report when a patient does not receive the 
necessary treatment. This is a significant finding as acts of omission have actually been 
implicated in twice as many adverse events as acts of commission (Wilson et al, 1995).  
A report published by the US Institute of Medicine in 1999 supported this finding by reporting 
that over one million preventable ADRs occurred each year in the US, with 44 000 – 98 000 
of these being fatal, and over 7 000 being due to medication errors (Kohn et al, 1999). These 
numbers are supported by a more recent South African study mentioned earlier conducted 
by Mouton and colleagues in 2013 where an alarming number of ADRs that caused hospital 
admission and deaths could have been prevented. 
Table 2.6. Characteristics of Most Common ADRs Causing Hospital Admission in Four 
Hospitals in South Africa (Mouton et al, 2013) 
 Renal 
Impairment 
Hypoglycaemia Drug-Induced 
Liver Injury 
Hemorrhage Blood 
Dyscrasias 
Number of 
ADR-related 
admissions 
24 22 20 19 14 
Drugs 
associated 
with the ADR 
TDF; ACE-I;co-
trimoxazole; 
rifampicin; co-
amoxiclav and 
ibuprofen 
Insulin;  
metformin; 
sulfonylurea; 
unspecified 
hypoglycaemic 
agent 
Rifampicin; 
efavirenz only; 
co-trimoxazole; 
enalapril; 
various 
combinations of 
ATT, NNRTIs, 
co-trimoxazole, 
erythromycin 
warfarin; 
acetylsalicylic 
acid; 
unspecified 
NSAIDs; 
diclofenac 
co-trimoxazole; 
zidovudine; 
lamivudine; 
stavudine; 
methotrexate; 
chloroquine; 
allopurinol; 
colchicine; 
rifampicin; 
isoniazid; 
amoxicillin; 
valproic acid 
Proportion 
preventable 
(%) 
73% 77% 13% 58% 30% 
Reasons for 
preventability 
(%): 
Inappropriate 
drug  
29% 32% 10% 0% 0% 
Inappropriate 
dose 
4.2% 18% 0% 21% 0% 
Inadequate 
monitoring 
17% 36% 0% 26% 7.1% 
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History of ADR 0% 18% 5% 21% 0% 
Interaction 0% 4.6% 0% 26% 0% 
Drug 
concentration 
0% 0% 0% 0% 0% 
Compliance 0% 14% 0% 0% 0% 
Combined all-
cause 
mortality (%) 
50% 18% 35% 16% 21% 
TDF = tenofovir; ACE-I = angiotension converting enzyme inhibitor; ATT = anti-tubercular treatment; 
NNRTI = non-nucleoside reverse transcriptase inhibitor; NSAID = non-steroidal anti-inflammatory drug   
 
2.6. ADVERSE DRUG REACTION RELATED COSTS 
Several studies have concluded that the cost of managing ADRs places a significant burden 
on health care budgets, not to mention the economic burden suffered by individuals and 
communities due to hospitalisation or mortality (Lundkvist & Jönsson, 2004). Some countries 
reportedly spend up to 15 - 20% of their hospital budgets managing drug complications 
(White, 2009). However, it has proved difficult to exactly quantify the economic burden of 
ADRs due to the vast number of factors involved. For example, one would need to consider 
days taken off work, additional doctors visits, and additional medications purchased or used 
for the management of complications.  
Lundkvist and Jönsson (2004) have surmised that in order to determine the economic impact 
of ADRs, it is necessary to look at two perspectives: the costs related to treatment of ADR 
outcome, and the cost of ADR avoidance. A number of studies aim to quantify the cost of 
“drug-related problems” rather than the cost of ADRs specifically (Philip et al, 1995; Johnson 
& Bootman, 1995). These estimates range from $1.5 million to $130 billion. In another study, 
ADR management during hospitalisation has been estimated to increase hospital costs by 
$2595 in 1997 (this figure can be presumed to be much higher now due to inflation and 
rising costs of hospitalisation (Classen et al, 1997). 
Figure 2.4 describes a situation where the decision to have higher costs for ADR avoidance 
reduces the probability of ADR occurrence. Lundkvist and Jönsson name four key role 
players involved in drug utilisation for whom ADRs could have an economic impact: patients 
(whom might obviously be affected by the cost of managing an ADR related disease or 
illness, or for the cost of revisiting physicians or the purchasing of different drugs to avoid 
ADRs), physicians (who operate in an environment where time spent with a patient, as well 
as number of patients seen within a given time period, is directly related to the amount of 
money they will earn. It is therefore not necessarily in a physician’s best monetary interest to 
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spend more time with a patient, explaining side effects and other effects of the drug), 
pharmacists (the management and other subsequent drug-related effects might lead to 
higher medicine-related spending for the management of these ADRs) and drug 
manufacturers (for whom an unexpected serious ADR might lead to a massive economic 
loss, but for whom spending more money and resources during clinical trials might lead to a 
loss in investment and time on market).  
Figure 2.4. Lundkvist and Jönsson’s comparison of cost of treating ADRs vs. cost of 
ADR avoidance (Cmin: minimum total costs; Iopt optimal incidence of ADRs (Lundkvist 
and Jönsson, 2004) 
 
It is also necessary to consider smaller but not insignificant ADR related economic impacts 
on individual patients. For example, the management of opioid-related ADRs. A patient that 
experiences constipation from licit or illicit opioid use might spend more money on laxatives 
and related products (including foods high in fibre, etc) to ease the constipation. To explore a 
more socio-economic perspective, a patient that becomes addicted to opioid painkillers and 
later begins to experience other addiction related behaviours (such as theft, unemployment, 
heroin-use, methadone-treatment, etc) will suffer a diverse variety of economic setbacks  
that is difficult to quantify but vital to understand in the greater setting of ADR-related costs. 
2.7. TYPES OF ADVERSE DRUG REACTION REPORTS  
There are a number of methods of ADR reporting currently employed both in South Africa 
and abroad.  
The most common and efficient method is the Spontaneous Reporting System (SRS), also 
known as ICSRs whereby HCPs or patients/consumers report an ADR to their respective 
pharmacovigilance centers when they become suspicious of a reaction (Joubert & Naidoo, 
2016). It is a voluntary, passive form of reporting that is extremely cost-effective and can be 
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a powerful tool to improve the safety of medicines worldwide provided that all HCPs actively 
participate. The SRS not only allows for the identification of new and rare ADRs (such as the 
fatal severe rhabdomyolysis seen with cerivastatin leading to its withdrawal in 2001) but 
allows for the continuous monitoring of all medicines used in “real life” situations (such as the 
recent finding that ACE-Is increase the risk of angioedema threefold in black patients 
compared to non-black patients) (Furberg & Pitt, 2011; McDowell et al, 2006).  
Other methods of reporting include Cohort Event Monitoring (CEM) and Targeted 
Spontaneous Reporting (TSR). CEM is a prospective, observational, cohort study of adverse 
events associated with one or more medicines. A CEM program is an observation of a new 
medicine in routine clinical practice in the early post-marketing phase, although it may also 
be used for older medicines. TSR is a methodology that builds on the principles of the SRS 
but is applied in a defined setting. TSR may be adapted either to report all suspected 
reactions in a defined population (such as in a nursing home or palliative care facility), or to 
focus only on specific reactions of particular concern (such as the monitoring of ADRs when 
trialling a new TB regimen). This serves to limit the reporting workload associated with 
adverse events that are most significant to individuals and programmes in question. CEM 
can be an expensive initiative, while TSR required complete commitment from HCPs (Pal et 
al, 2013). Identifying specific risk factors and high-risk groups, as well as providing valid 
clinical characteristics of problems associated with specific medicines, requires methods of 
greater scientific rigour (Pal et al, 2013).  
2.8. UNDERREPORTING 
Underreporting of ADRs and the reasons for it has been well documented in literature. 
Studies around the world have targeted HCPs (doctors, nurses and pharmacists) to gain a 
better understanding of their knowledge, attitudes and practices regarding ADR reporting. 
Studies depicting the knowledge, attitudes and practices of HCPs regarding ADR reporting 
vary widely. in general, doctors in developed countries (such as the UK, USA and the 
Netherlands) tend to have a better understanding of their respective ADR reporting systems 
than their counterparts in developing countries (such as India, Nigeria and Uganda) 
(Oshikoya et al, 2009). Interestingly, studies within the same country also produced different 
results. For example, the findings of a 2009 study in Nigeria in a teaching hospital concluded 
that doctors had inadequate knowledge regarding ADR reporting (Oshikoya et al, 2009). 
However, a similar study being performed at the same time yet in a different region of 
Nigeria, surmised that doctors did indeed have a good level of ADR reporting knowledge 
(Enwere et al, 2008). Inconsistencies such as these demonstrate the underlying issues 
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plaguing effective PV systems worldwide. It is not enough for one hospital or one region to 
excel in their PV efforts while the reporting rate for the country overall is not yet acceptable.  
2.8.1. KNOWLEDGE OF PHARMACISTS 
Literature indicates that one of the major reasons for pharmacists having insufficient 
knowledge regarding ADR reporting is the lack of presence of national pharmacovigilance 
centres (NPCs). Pharmacists in countries such as South Africa, Turkey and Nepal cite a lack 
of feedback and involvement on the part of their respective NPCs as their reasons for 
inadequate knowledge (Ruud et al, 2010; Toklu et al, 2008; Palaian et al, 2011). Because of 
the lack of presence, pharmacists are ether unsure or unaware of the location of their NPCs, 
procedures to follow for getting in contact, or what happens to an ADR report if it is in fact 
submitted (Palaian et al, 2011). 
2.8.2. KNOWLEDGE OF NURSES 
Although ADR reporting was not considered to be a professional obligation for nurses until 
recently, several studies conducted in Iran, China and Australia have concluded that nurses 
have an acceptable level of overall ADR reporting knowledge (Hajebi et al, 2010; Li et al, 
2004; Evans et al, 2006). A finding by Evans and colleagues in Australia concluded that 
nurses had a higher degree of ADR reporting knowledge than doctors (81.9% vs 49.7%) 
(Evans et al, 2006).  
One of the biggest factors affecting the level of ADR reporting knowledge of nurses 
worldwide is the lack of visibility and awareness of PV centres. Numerous studies surmise 
that many HCPs, including nurses, are either completely unaware of a national PV 
centre/authority, or are aware of its existence but not of its location, purpose or function 
(Ganesan et al, 2016;  Palaian et al, 2011; Irujo et al, 2007; Hanafi et al, 2012; Raza and 
Jamal, 2015). 
2.8.3. ATTITUDES OF PHARMACISTS 
The reasons for low reporting of ADRs by HCPs have been well researched. Lopez-
Gonzalez and colleagues released a systematic review mentioning ignorance (95%), 
diffidence (72%), lethargy (77%), indifference and insecurity (67%) and complacency (47%) 
as the primary reasons for underreporting (Lopez-Gonzalez et al, 2009). The paperwork 
involved with such reporting seems to discourage the desire to produce data of any sort, 
especially because those responsible perceive the data as irrelevant to their immediate 
clinical needs (Ruud et al, 2010). This is aptly illustrated by a finding from a study conducted 
in Nigeria where over 40% of pharmacists stated that patients had reported an ADR to them 
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in the preceding month, while only 20% of those pharmacists had reported the ADR 
(Oreagba et al, 2011). 
However, in developed countries, there seems to be a more positive attitude specifically 
amongst pharmacists towards ADR reporting as they considered it to be their professional 
obligation (Belton et al, 1995; Evans et al, 2006). Bearing this in mind, in a hospital 
environment, pharmacists are not always present by a patients bed side and directly 
monitoring their health outcomes in the same manner that doctors and nurses do. In this 
respect, inexperienced or unaware HCPs that lack the sound clinical judgement needed to 
determine a causal relationship between an adverse or unexpected event and a drug could 
pose as a great challenge (Suleman, 2010). 
2.8.4. ATTITUDES OF NURSES 
Largely, nurses seem to have the most positive attitude towards ADR reporting of all health 
care professionals including pharmacists (Evans et al, 2006; Wilson et al, 2008, Hajebi et al, 
2010).  
An interesting point to make is the difference in attitude between nurses in developed and 
developing countries. While nurses from all socioeconomic backgrounds believe ADR 
reporting to be an important aspect of medicine management, those from developed 
countries tend to have more motivation to monitor effects to new/experimental drugs when 
compared to those from developing countries (Green et al, 2001; Bateman et al, 1992; 
Belton et al, 1995; Desai et al, 2011; Mulatu and Worku, 2014; Suyagh et al, 2015). As 
stated previously in this chapter, this could be due to developed countries having had PV 
structures in place for a longer period of time and therefore have had more time to establish 
more sophisticated frameworks that actively include and educate all HCPs.  
2.8.5. PRACTICE OF PHARMACISTS 
Factors relating to processes for reporting, such as inadequate feedback, long forms and 
insufficient time to report, are often identified as major barriers to reporting (Uribe et al, 
2002). A pharmacist interviewed in a study conducted by Ruud and colleagues aptly stated, 
“…you report in a vacuum. You give it to somebody and you never hear again. And it’s nice 
to get feedback, from whoever who are collecting these ADRs to say, look, this is what we’re 
looking for, this is not what we’re looking for.” (Ruud et al, 2010). This statement is 
supported by a previous study conducted by Evans and colleagues whereby 58% of HCPs 
involved in the study cited a lack of feedback as a self-perceived barrier to reporting (Evans 
et al, 2006). Within a South African context, pharmacists in a study conducted by Joubertand 
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Naidoo in 2016 felt PV centres to be inaccessible with little to no personal contact (Joubert & 
Naidoo, 2016). Other self-perceived barriers included the form taking too long to complete, a 
lack of time, not wanting to take responsibility for the report and believing that the report will 
not make any difference (Evans et al, 2006). 
2.8.6. PRACTICE OF NURSES   
While ADR reporting practices of nurses vary, it would appear that reporting still remains a 
challenge worldwide. During completion of surveys, most nurses state that they have never 
encountered an ADR before (Hajebi et al, 2010; Li et al, 2004; Evans et al, 2006; Wilson et 
al, 2008). This figure is difficult to believe considering the number of patients seen to and the 
volume of medicines used in the presence of nurses within a hospital environment. However, 
this may be attributed to a lack of training with regards to the identification of ADRs 
(Suleman, 2010).  
However, many nurses do informally report ADRs to consulting doctors, nursing managers 
and pharmacy with varying extents.  
2.9. CONCLUSION 
As illustrated by the literature discussed, ADRs are an imminent and immediate public health 
threat. Unfortunately, there are many drugs that will not have a favourable benefit to risk 
ratio. However, by utilising effective PV systems, it will be possible to minimise the risks 
experienced by patients through ensuring that the medicines they use have an established 
safety profile. The biggest challenge when it comes to the management of ADRs is their 
underreporting by HCPs. In many countries, patients are allowed and even encouraged to 
submit their own ADR reports if they suspect that they are experiencing an ADR. However, 
many patients are simply unaware that they are able to do this and therefore rely on their 
HCPs to take action when there is a suspected ADR. In countries such as South Africa, 
where the population is large and extremely diverse, the safety profile of each medicine will 
not necessarily be the same across the population. It is therefore vital that HCPs in all 
healthcare sectors begin to integrate PV into their daily clinical practice and begin to 
consider ADR reporting as a professional obligation.  
A systematic review conducted by Onakpoya and colleagues in 2016 cited 462 medicinal 
products withdrawn worldwide due to ADRs with case reports and anecdotal evidence of 
ADRs used as evidence of withdrawal in 71% of cases from 1953 – 2013 (Onakpoya et al, 
2016). This median interval for withdrawal after the first report was 8 years, and the rate of 
withdrawal was significantly lower in African countries than on other continents. As 
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supported by Table 2.2, this highlights the lack in regulatory co-ordination between medicine 
regulatory authorities and medicine use.  
Considering that case reports are so important in removing drugs from the market where the 
risk profile significantly outweighs the benefits, it is vital that reporting of ADRs by HCPs be 
encouraged. 
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CHAPTER 3 
METHODOLOGY 
3.1. INTRODUCTION 
This chapter covers the general design of the study as well as the development and 
distribution of the questionnaire used. The study population, study setting and data 
instruments are described. It further elaborates on how validity and reliability models were 
utilised at various stages of the study.  Lastly, this chapter elucidates on the limitations of the 
study as well as ethical committees that approved the research. 
3.2. AIMS AND OBJECTIVES 
3.2.1. AIM 
This study aimed to evaluate the knowledge, attitudes and practices of pharmacists and 
nurses in the private hospital sector towards ADR reporting. 
3.2.2. OBJECTIVES 
I. Assessed the knowledge of private sector HCPs regarding the ADR reporting 
process in South Africa. 
II. Assessed the attitudes of private sector HCPs towards ADR reporting and varying 
components of ADR reporting.  
III. Evaluated ADR reporting practices of private sector HCPs. 
IV. Established factors that contributed to differences in both knowledge and attitudes 
towards ADR reporting. 
V. Explored trends that interfered with effective ADR reporting.  
3.3. STUDY DESIGN 
This study was a cross-sectional, observational, questionnaire-based study that involved 
registered nurses and hospital pharmacists working in the private sector within a single 
hospital group. 
3.4. STUDY POPULATION 
This study was conducted in six private hospitals and clinics within a single hospital group in 
Johannesburg, South Africa. These hospitals were selected as a result of a purposive 
sampling method as each hospital offers a variety of wards and specialties (i.e. maternity, 
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paediatrics, oncology, ICU, neurology, psychiatry, gynaecology, orthopaedics, neonatology 
and surgery), and provides both in- and out-patient facilities. It was therefore possible to 
include a study population with varying training and specialties, and therefore a broader 
spectrum of results was achieved.  
While there have been previous studies exploring the knowledge, attitudes and practices of 
HCPs towards ADR reporting, these have so far all been conducted in the public sector 
(Dheda, 2013; Nlooto & Sartorius, 2015; Dheda et al, 2016; Joubert & Naidoo, 2016; 
Segomotso, 2011; Roux, 2014). The private sector has seldom if ever been studied in this 
way. The Department of Health Master Procurement Catalogue 2017 identifies 476 
medicines available in the public sector (to be amended when necessary at the discretion of 
any relevant Pharmacy and Therapeutics Committees (PTC) in line with the WHO Essential 
Drugs List (EDL) guidelines). The private sector, on the other hand, is not limited by the 
Standard Treatment Guidelines (STG), EDL or state tenders, and therefore the number of 
medicines available for use by patients is larger and more varied.  The private sector sees a 
larger number of originator medicines, wider range of generic medicines, greater quantity 
and distribution of new medicines, as well as higher usage of experimental drugs compared 
to the public sector. This increase in availability of medicines may lead to an increase in the 
incidence of ADRs, and therefore a greater effort to target post-marketing surveillance in this 
sector should be made. 
Hospital pharmacists and registered nurses were selected as the study population due to 
their roles within the multi-disciplinary health care team. Registered nurses have twenty four 
hour access to the patient and are directly involved in their care. They are responsible for 
drug administration and are usually the first point of contact when a patient experiences a 
beneficial or harmful response to a drug. Hospital pharmacists have the pharmaceutical 
and/or clinical knowledge to detect or manage ADRs by virtue of their profession. 
Additionally, because many private hospitals in South Africa also provide retail pharmacy 
services, and therefore are able to supply chronic and over the counter (OTC) medicines, 
hospital pharmacists do tend to have direct access to patients. Because of the multi-
disciplinary health care model employed in most hospitals globally, it is important to evaluate 
the knowledge, attitudes and practices of both these professions towards ADR reporting. 
Doctors were excluded from this study due to a lack of willingness to participate during 
piloting. 
Inclusion criteria for participants were as follows: 
- Registered nurse or hospital pharmacist employed at the facility (locum and agency staff 
included) 
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- Willingness to participate (signed informed consent and/or completed questionnaire) 
Exclusion criteria were as follows: 
- Non-willingness to participate 
- Enrolled nurses (i.e. have not yet completed their qualification) 
- Support pharmacy staff (i.e. assistants, technicians and drug controllers) 
According to a study conducted by Econex on behalf of the South African Private 
Practitioners Forum (SAPPF) and Healthman (Pty) Ltd, The South African Private 
Healthcare Sector: Role and Contribution to the Economy, there were an estimated 77 569 
nurses and 2 984 pharmacists working within the South African private sector, as at 2013 
statistics (Econex, 2013). Assuming a ratio of approximately 0.9 registered nurses to 
enrolled nurses applicable throughout both public and private sectors (obtained from the 
South African Nursing Council Annual Statistics for Persons on the Register 2015), an 
estimated 72 000 registered nurses can be identified working within private institutions in 
South Africa. Similarly, South African Pharmacy Council Statistics show 290 private 
institutions registered in South Africa in 2016. Assuming that each private institution employs 
at least one pharmacist, at least 290 pharmacists can be identified as hospital pharmacists 
in the private sector. 
Therefore, a sample size of 382 was calculated, using a confidence interval (CI) of 5 and a 
confidence level (Z) of 95%, as per the formula below: 
Sample Size:  
𝑠𝑠 =  
𝑍2 × 𝑝 × (1 − 𝑝) 
𝐶2
 
 
Correction for finite population:  
𝑁𝑒𝑤𝑠𝑠 =  
𝑠𝑠
1 +  
𝑠𝑠−1
𝑝𝑜𝑝
 
Where: 
ss = sample size 
Z = Z-value (e.g. 1.96 for 95% confidence level) 
p = percentage picking a choice expressed as a decimal (0.5 used for sample size 
needed) 
C = confidence interval expressed a decimal (e.g. 0.05 = ± 5) 
pop = population  
3.5. QUESTIONNAIRE DEVELOPMENT 
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A self-administered questionnaire was used as the primary data collection tool. It had been 
adapted from similar studies investigating the knowledge, attitudes and practices of ADR 
reporting amongst HCPs and modified to suit a South African private sector setting (Jose et 
al, 2014; Rajiah et al, 2016; van Hunsel et al, 2010; Gupta &Udupa, 2011; Kiran, 2014).  
The questionnaire contained 20 close-ended questions, with four of these providing an 
opportunity for an open-ended answer in the form of a “Other – please specify” option. 
The questionnaire was designed to capture the following information, and can be found in 
Appendix A: 
• Participant information and demographic (four questions). This included gender, 
age, profession and years of experience. This was to determine whether differences 
in these variables contribute to differences in knowledge, attitude or practice (i.e. 
distinguishing between different demographics might indicate the extent to which 
they place predicate on ADR reporting). 
• Background knowledge of the participant with regard to ADR reporting (six 
questions). This included previous training received, knowledge of ADR reporting 
form, where the ADR reporting form is located, and where reports should be 
submitted. This was to determine the baseline knowledge of each participant towards 
ADR reporting and the ADR reporting process. This also aided in determining the 
level of previous exposure of each participant to ADRs and/or ADR reporting. 
• Participant perceptions towards ADR reporting (five questions). This included 
each participant’s perceived importance of ADR reporting in general, important or not 
important reasons for ADR reporting, factors that encouraged or discouraged the 
participant to report an ADR, and which kind of ADRs the participant thought should 
be reported. This was to aid in determining the general attitudes of the participants 
towards ADR reporting and attempted to identify factors outside of the participants’ 
knowledge that may contribute to low reporting rates. 
• ADR reporting practices of participants (five questions). This included whether 
the participant had come across an ADR previously, whether they have previously 
reported an ADR, the likely circumstances under which the participant would submit 
an ADR report, and which medical professional the participant deems responsible for 
submitting ADR reports. This was to gain an understanding of the current ADR 
reporting practices of each participant in order to determine how it can be improved. 
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3.6. QUESTIONNAIRE DISTRIBUTION 
The questionnaire was distributed to potential participants during the period June 2016 and 
December 2016. The questionnaire was distributed in two ways: electronically via e–mail to 
participants with regular computer and e-mail access at their workplace, and manually via 
hard copies to participants without regular access to a computer or e-mail at their workplace.  
3.6.1. ELECTRONIC DISTRIBUTION 
A list of e-mail address for potential participants was obtained from the Pharmacy and 
Nursing Managers of each respective hospital. A total of 83 potential participants were 
identified for electronic questionnaire distribution, and included pharmacists, locum 
pharmacists and registered nurses. The registered nurses identified for electronic distribution 
all held senior or managerial positions. All other nurses did not have regular access to 
computer or e-mail at their workplace and were thus considered for manual questionnaire 
distribution. 
An e-mail detailing the nature of the study in the form of an information sheet (Appendix B), 
informed consent document (Appendix C), and a link to the questionnaire was sent to each 
potential participant. Participation was completely voluntary and no incentives were offered. 
3.6.2. MANUAL DISTRIBUTION  
Hard copy questionnaires (including information sheet and informed consent document) 
were distributed to all potential participants without regular access to computer or e-mail at 
their workplace after holding a brief meeting with the staff of every unit/department in each 
identified hospital. The meeting served to provide each potential participant with the same 
information contained in the information sheet and informed consent document (Appendix B 
and C). An excess number of questionnaires were provided to the manager of each 
unit/department for distribution to night staff and staff that were on leave or were otherwise 
absent. Potential participants included pharmacists, registered nurses, and agency staff 
(nurses that were not directly employed by the hospital group but were outsourced from a 
nursing agency). Participants were provided with a period of one month to complete the 
questionnaire. A total of 360 questionnaires were involved in the manual distribution. 
Participation was completely voluntary and no incentives were offered. 
3.7. DATA COLLECTION 
Electronic questionnaires were captured onto Google Forms™ as they were completed. 
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For manually distributed questionnaires, a contact person was identified in each hospital 
(either the Senior Pharmacist or the Pharmacy Manager) from whom all the questionnaires 
were collected.  Regular e-mails were sent to the managers of each unit/department to 
remind their staff to complete the questionnaire should they wish to participate, hand in the 
questionnaires to the relevant contact person at their hospital, and to remind both managers 
and staff to contact the principal investigator should there be any questions or concerns. 
3.8. VALIDITY AND RELIABILITY 
Validity and reliability will be discussed in terms of the theories and criteria laid out by 
Maxwell (1992), Polit&Hungler (1997) and Onwuegbuzie& Johnson (2006) for evaluating 
qualitative, quantitative and mixed research methodologies.  
Table 3.1. Threats to Internal Validity 
Threat Definition Applicability to 
current study 
What was done to 
minimise the effect 
Implementation 
bias 
Occurs when the 
designed protocol is 
not followed in the 
intended manner 
Can occur if the 
protocol used for 
administration of 
questionnaire is not 
the same for all 
HCPs (i.e. time of 
administration, 
method of 
administration) 
An electronic 
platform, Google 
Forms™, was used 
to collect data for 
suitable participants 
while paper 
questionnaires were 
used for all other 
participants. 
Completion of 
questionnaires was 
entirely voluntary and 
participants were 
able to complete 
them at a time suited 
to them. 
Attrition Occurs when 
participants who 
have been selected 
to take part in the 
study do not take 
Can occur when 
potential research 
participants forget to 
complete the 
questionnaire. 
All participants were 
reminded on a 
weekly basis to 
complete the 
questionnaire. Data 
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part at all, or partially 
or completely fail to 
take part in various 
stages of the 
research process. 
collection took place 
over a period of six 
months. 
Researcher bias  Occurs when the 
researcher has a 
personal 
bias/preference 
towards a technique 
The researcher may 
create a 
predetermined 
hypothesis regarding 
the results that were 
obtained with the 
various testing 
procedures. 
Two types of data 
collection 
instruments were 
used – an electronic 
platform (Google 
Forms™) and paper 
questionnaires. 
Content validity Refers to how 
accurately an 
assessment tool 
represents the 
various aspects of 
the specific construct 
in question. 
Can occur when 
questions included in 
a questionnaire are 
too vague or broad. 
Questions were 
selected and 
adapted based on 
previously conducted 
similar studies 
measuring the same 
outcomes in different 
settings. 
Face validity The degree to which 
a test subjectively 
measures what it is 
supposed to 
measure. 
Can occur when 
questions might 
appear ambiguous, 
double-barrelled or 
otherwise difficult for 
the study population 
to answer 
The questionnaire 
was piloted on a 
represation (i.e. four 
locum pharmacists, 
one clinical 
pharmacist, ten 
agency nurses). 
Amendenments and 
adjustments to the 
questionnaire were 
made accordingly 
after receiving 
feedback. 
Sample integration 
legitimation 
Refers to situations 
where the researcher 
Can occur when the 
study population is 
Locum pharmacists 
and agency nurses 
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would want to make 
statistical 
generalizations from 
the study population 
to a larger target 
population. 
restricted to one 
geographical region 
or contextual setting. 
were included in the 
study population that 
perform their 
services in a variety 
of settings and 
locations. An 
assumption was also 
made that at least a 
small portion of 
participants had 
been previously 
employed and/or had 
worked in a region 
other than that 
included in this 
study. 
Inside-outside 
legitimation 
The extent to which 
the researcher 
accurately 
represents an 
insider’s view and an 
observer’s view for 
purposes of 
descriptive and 
interpretive validity. 
Can occur when a 
researcher is 
ethnocentric or 
becomes too 
involved with the 
population being 
studied. 
A peer-review 
methodology to 
analyse raw data and 
the interpretation of 
raw data. An emic 
viewpoint was 
obtained from a 
clinical pharmacist 
initially used for 
questionnaire piloting 
in the employ of the 
hospital group, while 
the etic viewpoint 
was supplied by two 
colleagues at the 
University of the 
Witwatersrand. 
Conversion 
legitimation 
Refers to the 
inferences made 
after qualitising or 
Can occur when 
counts of observed 
data are taken out of 
Data was presented 
in more than one 
profile (i.e. 
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quantitising data   context, over-
counted, lead to an 
over-generalization 
or over-/under-
weighting 
comparative profile, 
modal profile, 
normative profile) in 
order to provide a 
narrative description 
that was as accurate 
as possible.  
History effect and 
maturation 
Refers to events that 
occur external to the 
test (i.e. events in the 
environment) as well 
as physical or 
psychological 
changes in the 
participants. 
Can occur when the 
environment of the 
population is not 
adequately controlled 
nor are the 
participants 
adequately 
monitored.  
It is not possible to 
exclude collusion, 
collaboration and 
cooperation between 
and amongst 
participants during 
the completion of the 
questionnaire. 
Additionally, there 
was no method of 
preventing 
participants from 
researching “correct” 
answers to the 
questionnaire prior to 
completion. 
 
Table 3.2. Threats to External Validity 
Threat Definition Applicability to 
current study 
What was done to 
minimise the effect 
Population validity Refers to the extent 
to which the findings 
can be generalised 
from the sample 
group towards a 
larger population. 
Due to external 
factors, the sample 
may not be 
representative of the 
population. 
Convenience and 
purposive sampling 
was used by the 
(See Sample 
Integration 
Legitimation) 
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researcher. 
Ecological validity The extent to which 
findings from a given 
study can be 
generalised across 
settings, conditions, 
variables and 
contexts. 
The data and final 
results in the study 
are dependent on the 
setting and location 
in which it is 
obtained.  
(See Sample 
Integration 
Legitimation) 
 
3.9. DATA ANALYSIS 
All data was captured by entering into Google Forms™ and then exported into Microsoft 
Excel 2016™. Descriptive data analysis was conducted using Microsoft Excel 2016™. Each 
variable category as coded with a number for ease of analysis. Pearson chi-squares were 
used for a test of association, as well as cross-tabulation methods for bivariate analysis.  
Results are presented by means of percentages and/or graphs depending on their 
appropriateness to the variable in question. The relationship between different variables (e.g. 
age of respondent vs. previous exposure to ADRs) was determined using a Pearson chi-
square at p < 0.05. Frequency analysis was also employed to assess differences in 
attitudes, knowledge and practices.  
3.10. LIMITATIONS 
An important limitation of the study was participant bias, i.e. only those who agreed to 
participate were able to fill in the questionnaire. The use of both e-mailed and paper 
questionnaires were each a limitation. E-mailed questionnaires were a limitation in that not 
every e-mailed potential participant had regular access to their e-mail. Additionally, the e-
mails might have been ignored, automatically sent to the spam folder, and/or sent to an e-
mail address that is no longer in use. The paper questionnaires proved to be a limitation in 
that hospital staff tend to shy away from paperwork of any sort due to an already heavy 
administrative workload, and therefore did not complete the questionnaire. 
3.11. ETHICAL CONSIDERATIONS 
Ethics clearance was obtained from the University of the Witwatersrand Human Research 
Ethics Committee to conduct this study (Ethics No. : M160238) (Appendix D). Clearance was 
also obtained from the hospital group involved in the study on condition of confidentiality 
(Approval number: 20160620-01) (Appendix E). Each potential participant was provided with 
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an information sheet detailing the nature of the study and any benefits or risks to choosing to 
participate (Appendix B). All potential participants were informed that should they decide to 
withdraw or not complete the study, no repercussions, consequences or penalties would be 
applied. Informed consent was obtained from each participant prior to completion of the 
questionnaire, either electronically or manually (Appendix C). 
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CHAPTER 4 
RESULTS 
4.1. INTRODUCTION 
This chapter presents the results obtained in the study firstly in a descriptive fashion, and 
later using descriptive statistics. Results are presented mostly in the form of frequencies and 
appear in either tabular or graphic form. A test of association was conducted utilising a 
Pearson chi-square with p < 0.05. Bivariate analysis is used to present relevant data where 
applicable and appropriate. A total of 443 questionnaires were distributed – 83 via electronic 
distribution and 360 via manual distribution. Of these, only 233 responses were obtained, 
providing a sample response rate of 52.59%.  
4.2. DEMOGRAPHICS 
A total of 233 HCPs completed the questionnaire. The majority of participants were 
registered nurses, and approximately a fifth were pharmacists. Table 4.1 elaborates on the 
demographics of the participants.  
Table 4.1: Frequency distribution of demographic characteristics (N = 233) 
Demographic 
Characteristics 
Frequency (N) Percentage (%) 
Profession 
Registered Nurse 183 78.5% 
Hospital Pharmacist 50 21.5% 
TOTAL 233 100% 
 
Gender 
Male 23 9.9% 
Female 210 90.1% 
TOTAL  233 100% 
 
Age 
18 – 29 years old 49 21.0% 
30 – 39 years old 71 30.5% 
40 – 49 years old 61 26.2% 
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50 years and older 52 22.3% 
TOTAL 233 100% 
Years of experience   
Less than 1 year 17 7.3% 
1 – 5 years 42 18.0% 
5 – 10 years 63 27.0% 
Longer than 10 years 111 47.6% 
TOTAL 233 100% 
 
4.3. KNOWLEDGE 
Figure 4.1. Participants’ Knowledge of ADR Reporting Form
 
Only 32.19% of participants had previously seen the ADR reporting form, while 76.39% did 
not know where it was located. Of those that had previously seen the form before, 60% knew 
where it could be located. Only 6.3% of participants that had not seen the form before knew 
where it could be found.  Table 4.2 (a - b) elaborates on the difference in knowledge 
between pharmacists and nurses.  
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Table 4.2. Participants’ Knowledge of ADR Reporting Form: (a) Have previously seen 
the MCC ADR form; (b) Know where to find MCC ADR form 
(a) Seen MCC 
ADR form  
Nurses N  
(expected cell total) [chi-square 
statistic) 
Pharmacists N 
(expected cell total) 
[chi-square statistic) 
Total N (%) 
Yes 40 (58.91) [6.07] 35 (16.09) [22.21] 75 (32.18%) 
No 143 (124.09) [2.88] 15 (33.91) [10.54] 158 (67.81%) 
Total 183 50 233 
(100.00%) 
Chi-square = 41.6973; DF = 1; p = 1.066-10 
Therefore, the result is extremely significant at p < 0.05 
(b) Know where 
to find MCC 
ADR form  
Nurses N 
(expected cell total) [chi-square 
statistic) 
Pharmacists N 
(expected cell total) 
[chi-square statistic) 
Total N (%) 
Yes 21 (43.2) [11.41] 34 (11.8) [41.75] 55 (23.61%) 
No 162 (139.8) [3.52] 16 (38.2) [12.9] 178 (76.39%) 
Total 183 50 233 
(100.00%) 
Chi-square = 69.5776; DF = 1; p = 7.346-17 
Therefore, the result is extremely significant at p < 0.05 
 
 
Over three quarters of participants had never received any type of pharmacovigilance or 
ADR reporting training (Table 4.3). Of those that had, 17 were pharmacists and 37 were 
nurses.  
Table 4.3: Previous pharmacovigilance/ADR reporting training received  (N = 233) 
Pharmacovigilance 
Training Received 
Nurses N  
(expected cell total) [chi-
square statistic) 
Pharmacists N 
(expected cell total) 
[chi-square statistic) 
Total N (%) 
Yes 37 (42.41) [0.69] 17 (11.59) [2.53] 54 (23.18%) 
No 146 (140.59) [0.21] 33 (38.41) [0.76] 179 (76.82%) 
Total 183 50 233 
(100.00%) 
Chi-square = 4.1891; DF = 1; p = 0.040685 
Therefore, the result is significant at p < 0.05 
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Over half of the participants did not know the process to follow when submitting an ADR 
report (Table 4.4). Despite the form being titled the MCC ADR reporting form, approximately 
a quarter of participants stated that reports should be submitted to the MCC (Table 4.6 and 
4.7). 
Table 4.4. Participant’s knowledge regarding how to fill out and submit an ADR report 
form 
Variable Frequency 
(N) 
Percentage 
(%) 
Mark the statement that applies to you: 
I know how to fill out and submit an ADR reporting form 69 29.6% 
My manager deals with all ADR reports 37 15.9% 
I don’t know the process to follow 127 54.5% 
TOTAL 233 100% 
   
Table 4.5. Relationship between previous PV training and knowledge regarding filling 
out and submission of ADR report form 
Pharmacovigilance 
Training Received 
I don’t know the 
process to 
follow N 
(expected cell 
total) [chi-square 
statistic) 
I know how to 
fill out and 
submit an ADR 
reporting form N 
(expected cell 
total) [chi-square 
statistic) 
My manager 
deals with all 
ADR reports N 
(expected cell 
total) [chi-
square statistic) 
Total N 
(%) 
Yes 15 (29.43) [7.08] 32 (15.99) [16.03] 7 (8.58) [0.29] 54 
(23.18%) 
No 112 (97.57) [2.14] 37 (53.01) [4.83] 30 (28.42) [0.09] 179 
(76.82%) 
Total 127 69 37 233 
Chi-square = 30.45; DF = 2; p = 2.442-7  
Therefore, the result is extremely significant at p < 0.05  
 
Table 4.6 presents deceptive results as participants were able to mark more than one option 
when asked where ADR reports are submitted. In reality, participants are very uncertain as 
to where reports are submitted as depicted in Table 4.7. 
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Table 4.6. Participant’s knowledge regarding submission of ADR report form 
Variable Frequency 
(N) 
Percentage 
(%) 
ADR reports are submitted to: 
Pharmacy Manager 91 39.1% 
Nursing Manager 55 23.6% 
Hospital Manager 7 3.0% 
Head Office 20 8.6% 
Medicines Control Council (MCC) 62 26.6% 
National Adverse Drug Event Monitoring Center (NADEMC) 39 16.7% 
I don’t know 109 46.8% 
TOTAL 233 100% 
 
When asked whether the respondent believes their respective hospital submits sufficient 
and/or appropriate ADR reports, 78.7% said they did not know. Only 4.3% of respondents 
indicated that they think their hospital submits appropriate ADR reports while 17.6% said 
they do not believe so.  
Table 4.7. Participant’s knowledge regarding submission of ADR report form 
(expanded) 
Variable Frequency 
(N) 
Percentage 
(%) 
ADR reports are submitted to: 
Pharmacy Manager 28 12.0% 
Nursing Manager 12 5.2% 
Hospital Manager 0 0.0% 
Head Office 1 0.4% 
Medicines Control Council (MCC) 8 3.4% 
National Adverse Drug Event Monitoring Center (NADEMC) 6 2.6% 
I don’t know 96 41.2% 
Pharmacy Manager; Head Office; MCC 4 1.7% 
Pharmacy Manager; Head Office; MCC; NADEMC 2 0.9% 
Pharmacy Manager; MCC 8 3.4% 
Pharmacy Manager; MCC; I don’t know 3 1.3% 
Pharmacy Manager; MCC; NADEMC 8 3.4% 
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Pharmacy Manager; MCC; NADEMC; I don’t know 1 0.4% 
Pharmacy Manager; NADEMC 3 1.3% 
Pharmacy Manager; Nursing Manager 8 3.4% 
Pharmacy Manager; Nursing Manager; Head Office 3 1.3% 
Pharmacy Manager; Nursing Manager; Head Office; MCC 2 0.9% 
Pharmacy Manager; Nursing Manager; Head Office; MCC; 
NADEMC 
1 0.4% 
Pharmacy Manager; Nursing Manager; Hospital Manager 2 0.9% 
Pharmacy Manager; Nursing Manager; Hospital Manager; 
Head Office; MCC; NADEMC 
5 2.1% 
Pharmacy Manager; Nursing Manager; I don’t know 2 0.9% 
Pharmacy Manager; Nursing Manager; MCC 8 3.4% 
Pharmacy Manager; Nursing Manager; MCC; NADEMC 2 0.9% 
Pharmacy Manager; Nursing Manager; NADEMC 1 0.4% 
Head Office; MCC 2 0.9% 
MCC; I don’t know 1 0.4% 
MCC; NADEMC 7 3.0% 
Nursing Manager; I don’t know 6 2.6% 
Nursing Manager; NADEMC 3 1.3% 
TOTAL 233 100% 
 
4.4. ATTITUDE 
In total, three quarters of respondents thought that reporting ADRs was very important 
(Table 4.8). Opinions between nurses and pharmacists were similar with the exception of 3 
nurses believing ADR reporting to be not important. The difference in opinion between 
nurses and pharmacists can be seen in Table 4.8, and experience-related difference in 
opinion is presented in Table 4.9. 
Table 4.8. Importance placed on ADR reporting: Nurses vs. Pharmacists N (%) 
Importance Placed Nurses N (%) Pharmacists N (%) Total N (%) 
Very Important 133 (72.60%) 44 (88.0%) 177 (75.96%) 
Important 47 (25.68%) 6 (22.0%) 53 (22.75%) 
Not Important 3 (1.64%) 0 (0.0%) 3 (1.28%) 
Total 183 50 233 (100.0%) 
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Table 4.9. Importance placed on ADR reporting: Experience related N (%)  
Importance 
Placed 
Less than 1 
year N (%) 
1 – 5 years 
N (%) 
5 – 10 
years N (%) 
More than 
10 years N 
(%) 
Total N 
(%) 
Very Important 17 (100%) 27 (64.3%) 47 (74.6%) 86 (77.5%) 177 
(75.9%) 
Important 0 (0%) 15 (35.7%) 16 (25.4%) 22 (19.8%) 53 (22.7%) 
Not Important 0 (0%) 0 (0%) 0 (0%) 3 (2.7%) 3 (1.3%) 
Total 17 42 63 111 233 
 
Further opinions regarding the importance of different elements of ADR reporting are 
presented in Figure 4.2 (a – f) below. 
Figure 4.2. Differences in attitude of nurses and pharmacists towards varying 
elements of ADR reporting
 
 
0%
50%
100%
Nurses Pharmacists
Not Important 4.37% 0.00%
Important 15.30% 14.00%
Very Important 80.33% 86.00%
a) I think it is important to report ADRs to identify new 
ADRs
0%
20%
40%
60%
80%
100%
Nurses Pharmacists
Not Important 3.28% 2.00%
Important 27.87% 28.00%
Very Important 68.85% 70.00%
b) I think it is important to report ADRs to share 
information about ADRs with colleagues
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0%
20%
40%
60%
80%
100%
Nurses Pharmacists
Not Important 2.73% 2.00%
Important 16.39% 6.00%
Very Important 80.87% 92.00%
c) I think it is important to report ADRs to improve patient 
safety
0%
20%
40%
60%
80%
100%
Nurses Pharmacists
Not Important 3.83% 2.00%
Important 14.75% 10.00%
Very Important 81.42% 88.00%
d) I think it is important to report ADRs to help establish 
the safety of new drugs
0%
20%
40%
60%
80%
100%
Nurses Pharmacists
Not Important 3.28% 2.00%
Important 26.23% 18.00%
Very Important 70.49% 80.00%
e) I think it is important to report ADRs to measure the 
incidence or frequency of ADRs
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When asked which type of ADRs should be reported, most respondents thought that ADRs 
to all types of drugs should be reported. Only 22.3% believe that ADRs to new drugs should 
be reported (Table 4.10).  
Table 4.10. Which type of ADRs should be reported: Nurses vs Pharmacists 
Type of ADR Nurses N Pharmacists 
N 
Total N (%) 
None 1 0 1 (0.4%) 
All ADRs 169 34 203 (87.1%) 
All serious ADRs (causing death or serious 
injury) 
47 27 74 (31.8%) 
ADRs to medical devices (such as 
pacemakers, prosthetics, etc) 
24 19 43 (18.5%) 
ADRs to new drugs 28 24 52 (22.3%) 
ADRs to herbal, natural or traditional 
medicines 
18 12 30 (12.9%) 
 
Two respondents (both pharmacists) provided the following comments regarding which 
ADRs should be reported: 
- “All ADRs necessitating change of therapy.” 
- “ADRs not specified on package insert.” 
Table 4.11 below presents the suggestions from HCPs regarding how to improve reporting in 
their hospitals. 
0%
20%
40%
60%
80%
100%
Nurses Pharmacists
Not Important 4.92% 4.00%
Important 34.97% 40.00%
Very Important 60.11% 56.00%
f) I think it is important to report ADRs because it is a legal 
requirement
57 | P a g e  
 
Table 4.11. Suggestions on how the culture of reporting can be improved 
Suggestion Number N Percentage 
% 
ADR reporting made mandatory (i.e. will affect my monthly 
performance) 
40 17.2% 
Workshops and seminars 130 55.8% 
Pharmacovigilance teaching programmes for 
undergraduates, interns and postgraduates 
94 40.3% 
Monthly meetings discussing common ADRs that may be 
encountered 
122 52.4% 
Bring out bulletins/newsletters on ADRs 104 44.6% 
Getting paid a sum of money for each ADR reported 12 5.2% 
Other 4 1.7% 
Four participants provided additional comments regarding how to improve ADR reporting at 
their hospitals: 
- “When is a reaction an ADR. How to identify and determine when to report” 
- “Online reporting” 
- “Electronic submission process with instant feedback on status of the ADR reported” 
- “Access of ADR forms” 
Participants were provided with a number of general statements regarding their attitudes 
towards ADR reporting and asked to rate them on a scale of 1 to 5, with 1 being “Strongly 
Agree” and 5 being “Strongly Disagree”. The results are depicted in Figure 4.3 (a) – (d) 
below. 
Figure 4.3. General attitudes of participants towards ADR reporting 
 
67.80%
24.90%
4.70% 2.10% 0.40%
(a) ADR reporting is a professional obligation
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
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2.10% 6.00%
21.90%
26.20%
43.80%
(b) ADR reporting adds up to unnecessary 
workload
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
1.30% 4.30%
15.00%
27.90%
51.50%
(c) Nobody really benefits if I report an ADR
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
57.50%28.30%
9.40% 1.70% 3.00%
(d) I would like to receive more training on ADR 
reporting
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
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4.5. PRACTICE 
Only 18.9% of participants (i.e. N = 44) stated that they had previously reported an ADR. Of 
these, 13 respondents were pharmacists and 31 were nurses (Figure 4.4).  
When the participants were asked whether they had previously encountered an ADR and 
failed to report it, 13.7% of the total had indicated yes. Approximately two-thirds had marked 
no. The remaining 22.3% stated that they didn’t know, i.e. they were not sure if they had 
ever encountered an ADR.  
The majority of participants (75.5%) stated that they would most likely report all ADRs they 
encounter (Figure 4.5).  
Figure 4.4. Percentage of participants that have reported an ADR: Nurses vs 
Pharmacists (N = 233) 
 
Those that had previously received PV training were more likely to have reported an ADR in 
the past with a statistically significant result as per Table 4.12 
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No 83.06% 74.00%
Yes 16.94% 26.00%
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Table 4.12: Previous pharmacovigilance/ADR reporting training received vs. 
Likelihood of having reported an ADR in the past (N = 233) 
Previous PV 
training 
received 
Have reported an ADR 
before N (expected cell 
total) [chi-square statistic) 
Have not reported an ADR 
before N (expected cell 
total) [chi-square statistic) 
Total 
Yes 19 (10.2) [7.6] 35 (43.8) [1.77] 54 (23.2%) 
No 25 (33.8) [2.29] 154 (145.2) [0.53] 179 (76.8%) 
Total 44 189 233 
Chi-square = 12.1934; DF = 1; p = 0.00048 
Therefore, the result is significant at p < 0.05 
 
Figure 4.5. Likelihood that participants would report an ADR 
 
There were a number of factors that participants stated discouraged them from reporting 
ADRs. The frequency of these factors varied greatly, and is summarised below in Table 
4.13. In addition to the predefined factors, a number of comments were provided by 
participants (summarised below): 
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-  “Certainty as adverse reactions could be as a result of other factors not the 
treatment. It is difficult to know when a reaction is an ADR versus from some other 
cause” 
-  “Have not been in that situation yet” 
-  “Don’t know how to tell if ADR” 
- “None because I have no experience with doing such” 
- “Lack of training regarding reporting the ADR” 
- “This is my first time seeing the ADR form” 
- “Not knowing what an ADR is” 
- “No internal process for ADR” 
- “Not sure if it might be an allergic reaction that the patient did not know” 
Table 4.13. Factors that might discourage HCPs from reporting ADRs 
Factors N (%) 
Do not know how to report 108 (46.4%) 
Do not know where to report 81 (34.8%) 
Did not think it was important to report 18 (7.7%) 
Managing the patient was more important than reporting the ADR 27 (11.6%) 
Lack of access to ADR reporting form 80 (34.3%) 
Patient confidentiality might be breached 10 (4.3%) 
Legal liability issues 6 (2.6%) 
The form is too long 19 (8.2%) 
I don’t receive any feedback once the form has been sent 32 (13.7%) 
Other (summarised in comments above) 17 (7.3%) 
 
Table 4.14.highlights the discouraging factors between participants that claimed to have 
reported an ADR in the past versus those that had not. 
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Table 4.14. Discouraging factors for ADR reporting vs have previously reported an 
ADR 
Factor Have previously 
reported an ADR (%) 
Have not previously 
reported an ADR (%) 
Do not know how to report 31.8 50.3 
Do not know where to report 18.2 38.6 
Did not think it was important to 
report 
20.5 8.9 
Managing the patient was more 
important than reporting the ADR 
18.2 13.8 
Lack of access to ADR reporting 
form 
40.9 33.3 
Patient confidentiality might be 
breached 
2.3 4.8 
Legal liability issues 0 3.2 
The form is too long 13.6 6.9 
I don’t receive any feedback once 
the form has been sent 
40.9 7.4 
 
Participants also had an opportunity to indicate who they believe should be responsible for 
reporting/submitting ADR reports (Figure 4.6). A small portion of participants (4.7%), in 
addition to marking the boxes for doctors, nurses and pharmacists, marked the box for 
“Other” to state that they believe all HCPs should be responsible for reporting ADRs. One 
participant aptly stated, “...All the above professionals because they prescribe, dispense and 
administer these drugs to patients”. 
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Figure 4.6. People deemed responsible by the participants for reporting ADRs 
 
4.6 DESCRIPTIVE STATISTICS 
Data was coded according to a “most correct” or “most preferred” principle. Only thirteen 
questions were coded in this way due to the nature of the questions. The questions that 
were excluded included questions regarding participant demographics and questions of a 
personal and opinionated nature where there could be no “most correct” answer. Table 4.15 
elaborates on the coding method used for selected questions 
Table 4.15. Coding used for descriptive statistics per question (selected questions 
used for analysis) 
Question Variable Coding 
Have you ever received any pharmacovigilance or 
ADR reporting training? 
Yes – 1 
No - 0 
   
Have you ever seen the MCC ADR reporting form 
before? Please refer to the below form. 
Yes – 1 
No - 0 
   
Do you know where to find the MCC ADR reporting 
form?  
Yes – 1  
No – 0 
    
How important do you think it is to report ADRs? Very important – 2 
Important – 1 
Not Important – 0 
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Pharmacists 47 32 47 15 3
Nurses 133 140 111 15 8
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I think it is important to report ADRs to identify new 
ADRS 
(graded according to scale of 1 – 5 present on 
questionnaire) 
I think it is important to report ADRs to share 
information about ADRs with colleagues  
(graded according to scale of 1 – 5 present on 
questionnaire) 
I think it is important to report ADRs to improve 
patient safety 
(graded according to scale of 1 – 3 present on 
questionnaire) 
I think it is important to report ADRs to help 
establish the safety of new drug 
(graded according to scale of 1 – 3 present on 
questionnaire) 
I think it is important to report ADRs to measure 
the incidence or frequency of ADRs 
(graded according to scale of 1 – 3 present on 
questionnaire) 
I think it is important to report ADRs because it is a 
legal requirement 
(graded according to scale of 1 – 3 present on 
questionnaire) 
     
In your view, which ADRs should be reported? Answers containing “All ADRs” – 5 
Answers containing “All serious ADRs” – 4 
Other answers – 3 
None - 0 
   
Have you ever reported an ADR? Yes – 1 
No – 0 
    
Have you ever encountered an ADR and not 
reported it? 
No – 2 
I don’t know – 1 
Yes – 0 
    
Please mark the statement(s) that apply to you 
regarding the process to follow when reporting an 
ADR: 
I know how to fill out an ADR report form – 2 
My manager deals with all ADR reports – 1 
I don't know the process to follow – 0 
     
ADR reports are submitted to: Answers containing “MCC” or “NADEMC” – 3 
Answers containing “Pharmacy Manager” or 
“Nursing Manager” – 2 
Answers containing “Hospital Manager” or “Head 
Office” – 1 
I don’t know – 0 
    
In your opinion, which of these people should be 
responsible for reporting ADRs? 
All healthcare professionals – 3 
Singular answers – doctors, nurses or pharmacists 
– 2 
Patients – 1 
    
Do you think that your hospital submits sufficient 
and appropriate ADR reports? 
Yes – 2 
No – 2 
I don’t know – 1 
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ADR reporting is a professional obligation (graded according to scale of 1 – 5 present on 
questionnaire) 
ADR reporting adds up to unnecessary workload (graded according to scale of 1 – 5 present on 
questionnaire) 
Nobody really benefits if I report an ADR (graded according to scale of 1 – 5 present on 
questionnaire) 
I would like to receive more training on ADR 
reporting 
(graded according to scale of 1 – 5 present on 
questionnaire) 
 
The overall mean scores between both nurses and pharmacists were similar. However, a 
larger difference between the minimum and maximum scores was observed amongst nurses 
than pharmacists, although participants in the nursing group had the highest score. 
Questions utilised for coding included the assessment of knowledge, attitudes and practices 
of participants.  
Table 4.16. Descriptive Statistics - overall 
 N Mean Standard 
deviation 
Standard 
error 
95% confidence 
interval from 
mean 
Minimum Maximum 
 Lower 
bound 
Upper 
bound 
Nurses 183 39.44 4.43 0.33 38.79 40.09 26 51 
Pharmacists 50 41.94 3.41 0.49 40.97 42.91 36 49 
Total 233 39.96 4.33 0.28 39.40 40.52 26 51 
 
Pharmacists had a better overall mean score in respect of knowledge questions (Table 
4.17). This is consistent with other knowledge-related results presented above. Interestingly, 
the minimum and maximum scores for both nurses and pharmacists were the same.  
With respect to attitude related questions, nurses actually scored higher than pharmacists 
did (Table 4.18). This can imply that nurses hold an overall more positive view towards ADR 
reporting than pharmacists. 
The scores relating to practice relate questions were similar for both nurses and 
pharmacists. While there was a larger standard deviation seen amongst the pharmacists, 
improvement in this area would be valuable.  
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Table 4.17. Descriptive Statistics:Knowledge-related questions 
 N Mean Standard 
deviation 
Standard 
error 
95% confidence 
interval from 
mean 
Minimum Maximum 
 Lower 
bound 
Upper 
bound 
Nurses 183 3.54 2.36 0.17 3.20 3.88 1 10 
Pharmacists 50 6.86 2.84 0.40 6.05 7.67 1 10 
Total 233 4.25 2.82 0.18 3.89 4.61 1 10 
 
Table 4.18. Descriptive Statistics: Attitude-related questions 
 N Mean Standard 
deviation 
Standard 
error 
95% confidence 
interval from 
mean 
Minimum Maximum 
 Lower 
bound 
Upper 
bound 
Nurses 183 31.72 3.06 0.23 31.27 32.17 21 40 
Pharmacists 50 30.72 2.29 0.32 30.07 31.37 26 35 
Total 233 31.51 2.94 0.19 31.13 31.89 21 40 
 
Table 4.19. Descriptive Statistics: Practice-related questions 
 N Mean Standard 
deviation 
Standard 
error 
95% confidence 
interval from 
mean 
Minimum Maximum 
 Lower 
bound 
Upper 
bound 
Nurses 183 4.16 1.01 0.07 4.01 4.31 2 6 
Pharmacists 50 4.38 1.09 0.15 4.07 4.69 2 6 
Total 233 4.21 1.03 0.07 4.08 4.34 2 6 
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CHAPTER 5 
DISCUSSION 
5.1. INTRODUCTION 
This chapter will discuss the results obtained in the context of the study and make 
appropriate recommendations accordingly. It will compare results with similar studies 
conducted both in South Africa and internationally in order to place the study in both a local 
and global context. This chapter will also highlight the deficits in the knowledge, attitude and 
practices of HCPs in the private sector and discuss measures to improve on these deficits. 
5.2. DEMOGRAPHICS 
A total of 443 questionnaires were distributed – 83 via electronic distribution and 360 via 
manual distribution. Of these, only 233 total responses were obtained, providing a sample 
response rate of 52.59%. This is a lower response rate than was achieved in other similar 
studies (61% in India, 58.8% in Japan, 68.9% in South Africa) (Desai et al, 2011; Obara et 
al, 2016; Joubert& Naidoo, 2016)  
The majority of participants were registered nurses (78.5%). This corresponds to statistics 
provided by Econex on behalf of the South African Private Practitioners Forum (SAPPF) and 
Healthman (Pty) Ltd, The South African Private Healthcare Sector: Role and Contribution to 
the Economy whereby an estimated 77 569 nurses and 2 984 pharmacists were working 
within the South African private sector, as at 2013 statistics (Econex, 2013). 
Further, 90.1% of participants were female compared to 9.9% of participants who were male. 
This is consistent with South African Nursing Council Statistics for 2016 where the female to 
male ratio is approximately 10:1 (SANC, 2016). Although the South African Pharmacy 
Council statistics for 2016 provides a lower ratio of females to males at approximately 1.5:1, 
the lower number of pharmacists included in this study aptly contributes to the overall 
number of male and female participants (SAPC, 2016). 
The age distribution of participants was roughly equal with the larger proportion of 
participants being 40 years and older, and just under half of participants were younger than 
40 years old. Approximately half of the participants had been practicing for over 10 years, 
whereas only 7.3% had been practicing for less than a year with the majority of these being 
nurses. The small number of newly qualified nurses might be attributed to a finding by 
Armstrong and Rispel in 2015 that over the last few years, nursing as a profession has 
68 | P a g e  
 
become less attractive. It has become to be perceived as a job, rather than a vocation, with 
long and inflexible working hours, increased service demands, and poor salaries, thus 
reducing the number of students eager to study nursing (Armstrong and Rispel, 2015).  
5.3. KNOWLEDGE 
Approximately three quarters of participants had never received any PV training (Table 4.3). 
This finding is similar to one in Nigeria where only a third of participants in a similar study 
had undergone any PV training (Osakwe et al, 2013). A larger proportion of pharmacists 
than nurses have previously received PV or ADR reporting training, with a statistically 
significant result at p < 0.05. This result is as expected due to the fact that pharmacists are 
exposed more often to concepts such as ADRs and medication management by virtue of 
their profession. During their undergraduate degrees, pharmacists in South Africa are 
exposed to between three and four years of pharmacy practice training – focusing on legal 
and regulatory aspects of pharmacy amongst other things – and between two and three 
years of pharmacology – focusing on how medicines function in the body, including toxicities 
(sourced from the Bachelor of Pharmacy curricula of Rhodes University, University of 
Witwatersrand, Nelson Mandela Metropolitan University and University of Western Cape). 
To compare with a country with a higher ADR reporting rate than South Africa, such as the 
United States (77/million population in 2011 in South Africa vs. 2803/million population in 
2011 in USA (Maigetter et al, 2015; FDA, 2015)), pharmacist training is more or less 
equivalent regarding the number of years spent on pharmacology and pharmacy practice 
(sourced from PharmD curricula of the University of Southern Carolina, Ernest Mario School 
of Pharmacy, University of California San Francisco, and University of Maryland).  
In contrast, nurses in South Africa are typically exposed to only one year of pharmacology 
during their undergraduate training, with an additional focus on legal and regulatory aspects 
relevant to the nursing profession (sourced from the Bachelor of Nursing curricula of 
University of KwaZulu Natal, University of Witwatersrand, University of Pretoria and Nelson 
Mandela Metropolitan University). Nursing training will differ vastly from pharmacy training 
due to the vastly different fields and focuses, each with their own importance and roles in 
patient care.  
However, to have three quarters of participants in this study having received no PV training 
during their careers can be viewed as problematic. The population of patients seen in 
hospitals is often vulnerable and prone to the development of ADRs due to the 
polypharmacy often used. As illustrated by Mouton and colleagues in 2015 that ADRs 
contributed to the deaths of 2.9% of hospital admissions and 16% of total deaths in four 
South African hospitals (Mouton et al, 2015). By virtue of the type of patient presenting in a 
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hospital, a rudimental understanding of PV might be beneficial to these patients and to the 
general community as a whole.  
Interestingly, the number of years of experience of the respondent doesn’t present a 
statistically significant difference in whether any previous training has been received, but 
rather, the age of the participant seemed to have significance. While there is no clear trend 
dependent on age, respondents aged 50 years and older had a proportionally larger 
exposure (42.30%) to PV training. This could be intuitively attributed to simply having been 
in practice for a longer period of time than other respondents, however the correlation has 
proved to be statistically insignificant. This finding is similar to those of other studies 
assessing the knowledge, attitudes and practices of health care workers such as Palaian et 
al (2011). Other similar studies did not explore the relationship between age/number of years 
of experience and previous PV training. However, analysis done by Osakwe and colleagues 
in Nigeria found a positive relationship between previous PV training received and PV 
knowledge and practices. Those that had undergone PV training scored higher than those 
that had not in knowledge and practice (Osakwe et al, 2013). 
Table 5.1. Effect of training on knowledge scores of pharmacovigilance (Osakwe et al, 
2013) 
Received PV 
Training 
Good (%) Fair (%) Poor (%) 
Yes 48.9% 18.1% 33.0% 
No 17.0% 15.4% 67.6% 
 
Table 5.2. Effect of training on practice of pharmacovigilance (Osakwe et al, 2013) 
Received PV 
Training 
Good (%) Fair (%) Poor (%) 
Yes 26.6% 24.5% 48.9% 
No 15.4% 11.3% 73.3% 
 
Approximately a third of participants stated that they know how to fill out an ADR form (Table 
4.4). This corresponds to the third of participants that stated that they had previously seen 
the ADR form (Table 4.2). A copy of the form was attached with the questionnaire for 
participants to refer. This finding has proven to be difficult to compare with other similar 
studies as other studies seem to assume that the HCPs they are surveying have a base 
knowledge of the ADR form.  
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Participants that had previously undergone some kind of PV training were much more likely 
to know the process to follow when submitting an ADR with an extremely statistically 
significant p-value (Table 4.5). They were also more likely to have had reported an ADR in 
the past (Table 4.12). This finding is supported by numerous other sources that conclude 
that PV training increases the likelihood that HCPs will participate in PV activities such as 
ADR reporting (Zolezzi&Parsotam, 2005; Kulkarni et al, 2013). 
There were a small number of participants (8.5%) that had never seen the ADR form before 
yet marked that they knew how to complete the form. This might be attributed to the 
structure of the form. Bandekar and colleagues performed a review in 2010 on ADR forms 
from numerous countries and compiled a list of 18 points that should be present on an ADR 
form for it to be considered sufficient to collect data and efficient for use. ADR forms used in 
South Africa contain 12 of these points determined by Bandekar and colleagues (Bandekar 
et al, 2010). This implies that the MCC ADR form is sufficiently user-friendly, such that even 
a HCP that has never seen it before can complete it, and that it asks the HCP sufficient 
information that is readily available to them. 
Table 5.3. Assessment of South Africa’s ADR reporting form (Bandekar et al, 2010) 
Contents South African ADR form 
Patient Information Yes 
Pregnancy Status No 
Allergic Status Yes 
Diagnosis Yes 
Description of Reaction Yes (little space) 
List of Suspected Drugs Yes (six drugs including concomitant 
medication) 
Dose, Frequency of Drugs Yes 
Space for concomitant drugs Yes (no separate space available but is 
included in suspected drug column) 
Start Date and Stop Date of Suspected 
Drugs 
Yes 
Relevant History of Patient Yes 
Actions Taken No 
Severity No 
Causality No 
Outcome Yes 
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Dechallenge No 
Rechallenge Yes 
Treatment of ADR Yes 
Lot No., Expiration Date No 
 
The majority of participants stated that they did not know where the ADR form should be 
submitted. Despite the form being titled as the MCC ADR form, only about a quarter of 
participants noted that the form should be submitted to the MCC (Table 4.6). This finding is 
supported by numerous studies whereby HCPs are either completely unaware of a national 
PV centre/authority, or are aware of its existence but not of its location, purpose or function 
(Ganesan et al, 2016;  Palaian et al, 2011; Irujo et al, 2007; Hanafi et al, 2012; Raza and 
Jamal, 2015).  Joubert and Naidoo (2016) concluded in their study that pharmacists would 
like to see increased communication from local PV centres in South Africa. The pharmacists 
involved in their study viewed the PV centres as inaccessible with little to no personal 
contact (Joubert& Naidoo, 2016). However, there still appears to be a large amount of 
confusion regarding where ADR reports should be submitted as evidenced by Table 4.7. A 
large portion of participants in this study (approximately 40%) stated that forms should be 
submitted to the Pharmacy Manager. While not technically the correct response, it could be 
considered “most correct” as standard operating procedures (SOPs) in most institutions, 
including the hospitals used in this study, dictate that ADRs be reported to the Pharmacy 
Manager for further investigation and action. In many SOPs, it is the responsibility of the 
Pharmacy Manager to submit ADR reports to the medicines regulatory authority. 
When asked whether the respondent believes their respective hospital submits sufficient 
and/or appropriate ADR reports, an overwhelming 78.1% said they did not know. This 
indicates that staff are largely not informed in such matters. Additionally this might indicate 
that there are insufficient processes in place for the handling of ADR reports. This is 
exemplified by a comment provided by a participant on another question, “No internal 
process for ADR”. While there is an SOP for the management of ADRs within the hospital 
group in this study, it appears that there needs to be more awareness of it. In order to 
improve ADR practices in private institutions in South Africa, all HCPs should be aware and 
informed of the procedures for handling ADRs. 
5.4. ATTITUDE 
Overall, participants had a positive attitude towards ADR reporting, with most respondents 
considering ADR reporting, including varying elements of reporting, as important and very 
important. Only 3 nurses considered ADR reporting to be not important.  
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When asked which type of ADRs should be reported, most respondents thought that ADRs 
to all types of drugs should be reported. Only 22.3% believe that ADRs to new drugs should 
be reported. This is totally contradictory to findings in other studies conducted in developed 
countries where an overwhelming majority of HCPs believed ADRs to new products should 
be reported (99.3%, 90.4%, 91% respectively) (Green et al, 2001; Bateman et al, 1992; 
Belton et al, 1995).  Conversely, HCPs in developing countries had a similar attitude to this 
study in that 34.2%, 7.7%, and 57.0% of HCPs surveyed respectively believed that ADRs to 
new drugs should be reported (Desai et al, 2011; Mulatu and Worku, 2014; Suyagh et al, 
2015). This can be viewed as a problematic attitude as long-term harms to new drugs are 
often not known when they are first marketed. ADR observation and reporting should 
actually be considered a priority activity in the management of new drugs. 30 participants 
thought that ADRs to herbal, natural or traditional medicines should be reported. In South 
Africa, the total market for traditional medicines is estimated at approximately R 3 billion, 
with at least 27 million patients consuming traditional or herbal medicines annually (BMI, 
2010). The contents of traditional and herbal medicines are often unknown, and in some 
instances contain potentially harmful ingredients (Isah et al, 2012). 
Two respondents (both pharmacists) provided the following comments regarding which 
ADRs should be reported: 
- “All ADRs necessitating change of therapy” 
- “ADRs not specified on the package insert” 
An important way to improve ADR reporting is to ask participants directly for suggestions on 
how to improve ADR reporting at their respective institutions. More than half of respondents 
say that workshops and seminars, monthly meetings, and publication of bulletins/newsletters 
would improve the ADR reporting culture. The responses indicate that HCPs would prefer 
“in-house” methods to improve ADR reporting at their institutions. In this way, each institution 
would be able to constantly remind their HCPs about ADRs and their management. A 
comment provided by a participant noted that training regarding identification of ADRs would 
be effective. This corresponds with the comments provided by participants for another 
question regarding the likelihood of reporting ADRs (Figure 4.5) that HCPs are simply 
unaware or not confident enough to make a decision as to what constitutes an ADR and 
what action they should take. This finding supports those obtained internationally that 
varying degrees of unfamiliarity with the reporting process remains one of the biggest 
hurdles to efficient reporting (Grootheest, 1999; Evans et al, 2002).  
73 | P a g e  
 
Additionally, several participants noted that online or electronic reporting would be effective 
to improve reporting rates. Many HCPs in all environments are often overwhelmed with 
paperwork and thus tend to shy away from any additional forms that might be regarded 
irrelevant to their immediate clinical needs (Rudd et al, 2010). Considering that many 
workplaces, including hospitals, are moving towards being a paperless environment, 
electronic forms could save HCPs time and energy in all areas of patient management 
(Kutney-Lee and Kelly, 2011). 
5.5. PRACTICE 
Only 44 participants (18.9%) have ever reported an ADR before. This figure is lower than in 
others reported in other similar findings: 33.7% in Nepal, 32.0% in Nigeria, 22.8% in China, 
35.0% in the Netherlands, and 44.1% in a similar South African study (Palaian et al, 2011; 
Okezie, 2008; Li et al, 2004; Eland et al, 1999; Joubert& Naidoo, 2016). When the 
participants were asked whether they had previously encountered an ADR and failed to 
report it, 13.7% of the total had indicated yes. Approximately two-thirds had marked no, 
although this might have been attributed to the wording of the question, i.e. they had never 
encountered an ADR and therefore had not reported it.  Regardless of how the question was 
perceived, it is almost impossible for such a large majority to state that they hadn’t 
encountered an ADR, particularly being in a hospital environment. Simply by the nature of 
the drugs in use in a hospital setting, at least one ADR should have been encountered (e.g. 
morphine-induced constipation, or antibiotic-related diarrhoea and/or abdominal discomfort). 
The remaining 22.3% stated that they didn’t know, i.e. they were not sure if they had ever 
encountered an ADR. In this respect, workshops that focus on common ADRs that may be 
encountered in a hospital setting might assist in reducing the uncertainty experienced by 
HCPs. 
Older participants (aged 40 and older) were more likely than younger participants (aged 40 
and younger) to have reported an ADR in the past (21.48% vs. 16.07%) and were more 
likely to know the ADR reporting process (35.54% vs. 23.21%). This corresponds to a similar 
study by Evans and colleagues (2006) whereby senior nurses had a higher degree of 
involvement in the ADR reporting process than their junior counterparts.  
The majority of participants (75.5%) stated that they would most likely report all ADRs they 
encounter (Figure 4.5). Therefore, more effort to train these HCPs to report would be 
beneficial. If a similar intention to report all ADRs exists for the majority of HCPs, the process 
of reporting needs to be streamlined and made more efficient, as well as the provision of 
more integrated and intensive training regarding identifying and detecting ADRs. 
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There were a number of factors that participants stated discouraged them from reporting 
ADRs. The frequency of these factors varied greatly, and are summarised in Table 4.13. It is 
possible to surmise that the three biggest factors that prevent HCPs from reporting ADRs 
are not knowing how to report, not knowing where to report, and a lack of access to ADR 
forms. Most of the additional comments provided by participants exemplified the fact that 
HCPs are simply not educated and/or trained enough in the identification of an ADR. 
Admittedly, many ADRs might be quite subtle and difficult to distinguish from an actual 
clinical disease state. Sometimes it might be impossible to directly identify an ADR. In this 
respect, it is vital that all HCPs work together in order to utilize the expertise of all fields, i.e. 
clinical expertise of doctors, patient knowledge and care expertise of nurses, pharmaceutical 
knowledge of pharmacists. This is consistent with conclusions drawn by Lopez-Gonzalez 
and team in a systematic review performed to identify the determinants of ADR 
underreporting.  
Figure 5.1. Major factors contributing to underreporting ADRs: systematic review 
(Lopez-Gonzalez et al, 2009)
 
In this present study, participants mostly correctly identified the key role players in the ADR 
reporting process (doctors (77.2%); nurses (73.8%); pharmacists (67.8%) (Figure 4.6). 
However, only a small number (4.72%) thought that all HCPs are responsible for ADR 
reporting. This finding is supported by a similar study where only 8.8% of pharmacists 
correctly believed that all HCPs were role players in the ADR reporting process (Joubert& 
Naidoo, 2016). Hospital nurses have the potential to hold an important role in ADR detection 
and reporting because of their proximity to patients. They are unique in their position in drug 
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administration and the monitoring of responses to drugs, often acting as a messenger 
between patients and doctors and being responsible for alerting doctors to changes or 
differences in patients health state (Hanafi et al, 2012). 12.87% of participants (15 
pharmacists and 15 nurses) in this study thought that patients should be responsible for 
reporting ADRs. In practical terms, patients are not always suitably qualified to report ADRs 
due to a lack of knowledge or awareness and therefore better communication between 
patients and HCPs needs to be encouraged. In a study in Lagos, Nigeria, over 40% of 
pharmacists stated that patients had reported an ADR to them in the preceding month, while 
only 20% of those pharmacists had reported the ADR (Oreagba et al, 2011). While HCPs 
have the main responsibility of reporting ADRs, patients have been permitted and should be 
encouraged to report ADRs in countries such as South Africa in order to increase reporting 
rates (Khalili et al, 2012; Roux, 2014).  
5.6. LIMITATIONS 
The major limitation of this study was that it was conducted only within a single hospital 
group. It is possible that other hospital groups within South Africa, indeed even individual 
hospitals, place a greater emphasis on PV and ADRs. However, by including agency nurses 
and locum pharmacists in the study, it was assumed that they would have been exposed to 
other environments with other practices. Additionally, because HCPs in South Africa are 
required to spend at least one year in a public sector institution performing community 
service, it was hoped that at least some respondents would have had PV exposure during 
this time and carried it over into private practice. Additionally, doctors and prescribers have 
been excluded from this study. This was unfortunately due to a lack of willingness to 
participate during piloting and other pre-distribution phases of the study, and therefore, the 
results could have been interpreted differently if they had been including as participants.  
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CHAPTER 6 
CONCLUSION 
6.1. INTRODUCTION 
This chapter will conclude the dissertation by providing a brief summary of the results 
obtained in context of the research question. Further, it will provide recommendations based 
on the obtained results and provide some ideas for further study. 
6.2. SUMMARY OF RESULTS 
The knowledge of the participants of this study with respect to ADR reporting is inadequate. 
Regardless of their profession, the participants involved in this study did not provide 
satisfactory answers regarding the ADR reporting form and the processes involved with it, 
including who should be responsible for reporting. Largely it would appear that the primary 
reason for participants not knowing where the form must be submitted was that they had 
simply never seen the form before. However, the overall knowledge of participants regarding 
ADR reporting could be considered as acceptable considering that only approximately a 
quarter of participants had ever received any previous PV training. 
However, the overall attitude of participants to ADR reporting was overall quite positive. Most 
participants believed ADR reporting to be an important function of their job, with many of 
these agreeing that it was a professional obligation. A small cause for concern was the type 
of drugs participants believed should be reported, with only a small percentage believing 
ADRs to new drugs should be reported. Regardless, most respondents agreed that ADRs to 
all types of drugs should be reported.  
Participants provided useful suggestions as to how to increase the culture of reporting at 
their respective hospitals. Considering that many had received no previous PV training, a 
large number of participants suggested “in-house” methods of training such as workshops 
and seminars in order to familiarise themselves with both the identification of common ADRs 
as well as the process of ADR reporting. 
Although the overall knowledge is inadequate while the overall attitudes are quite positive, 
the transition into practice needs to be improved. A small percentage of participants had 
previously reported an ADR before. The three biggest factors that prevent HCPs from 
reporting ADRs are not knowing how to report, not knowing where to report, and a lack of 
access to ADR forms. In the greater scheme of things, these are minor issues that can be 
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easily rectified. Most of the additional comments provided by participants exemplified the fact 
that HCPs are simply not educated and/or trained enough in the identification of an ADR. 
6.3. RECOMMENDATIONS 
The biggest conclusion drawn from this study is that participants are not sufficiently exposed 
to PV in their careers. Therefore, the most important recommendation to be made is to 
emphasise PV during undergraduate studies, and to ensure that hospital staff are provided 
with a continuous exposure to PV or ADR workshops/seminars/training sessions. Because 
PV is fast becoming an integral part of managed health care worldwide, it is important that 
South Africa not be left behind in this regard. 
Additionally, one of the biggest factors that seemed to discourage participants from reporting 
was a lack of access to ADR reporting forms. In this respect, it is recommended that senior 
staff in the hospitals ensure that ADR forms are easily available and accessible for its health 
care professionals. It might be logical to assume that if health care professionals have 
greater access to the forms, they would be reporting more often, and vice versa.  
Hospital environments can be stressful and fast paced environments. The realistic likelihood 
of a hospital worker completing a long form that they do not perceive as important to their 
immediate clinical needs is small. Therefore, an online or electronic platform for the 
submission of ADRs is recommended. It will drastically reduce the time and energy required 
to complete a report and hopefully will lead to increased numbers. 
The final recommendation is to encourage greater cooperation and coordination between 
and amongst the medicine regulatory authorities and health care professionals. The MCC, 
NPC and other bodies involved with PV need to determine a way to centralise and 
streamline the ADR reporting process. In this way, it will be possible to drastically reduce 
confusion or uncertainty amongst health care professionals. In addition, the MCC needs to 
make an effort to have a bigger presence. If ADR reporting could be actively promoted to 
both patients and health care professionals, the likelihood of reporting could be increased 
due to this increased awareness. Finally, there needs to be a greater cooperation amongst 
health care professionals utilising the expertise and skill of each profession. For example, 
pharmacists and doctors are not typically involved in the twenty four hour care of the patient, 
yet nurses are. Therefore, if a nurse caring for a patient notices a change in the patients 
state after administration of a medicine, she/he should be responsible for consulting with the 
doctor or pharmacist in order to determine if a potential ADR might be detected.  
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6.4. RECOMMENDATIONS FOR FUTURE STUDIES 
Going forward, a number of different approaches could be utilised in order to effectively 
determine the status of PV in the South African private sector. Firstly, a similar study could 
be conducted in the other major hospital groups in the country in order to paint a more 
complete picture of the knowledge, attitudes and practices of ADR reporting in the private 
sector.  
Alternatively, a more hands-on study could be undertaken in which an electronic platform is 
developed that could assist with ADR reporting rates in this particular hospital group. If 
something like that is not feasible in the short term, a study comparing changes in 
knowledge, attitudes and practices before and after the implementation of a 
workshop/training session could be conducted. 
6.5. CONCLUSION 
In reality, improving PV in South Africa is an effort that must be based at national level. 
However, while those at national levels are slowly implementing improvements and changes, 
hospitals and clinics with the ability and resources to implement their own improvements 
should be encouraged to do so. Generally, attitudes of “one report will not make a 
difference” need to be discouraged. Even if every private hospital in the country submits one 
report, it will make a difference in the certainty of the safety profile of a particular drug. 
Particularly in the private sector where there is a massive expenditure per annum on 
medicines, it can only benefit the population to increase the reporting rate.  
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APPENDIX A:  
QUESTIONNAIRE 
Dear Participant: 
This questionnaire may contain words that you do not understand. Please ask the 
investigator to explain any words or information that you do not clearly understand. For 
your information: 
Definitions: 
Adverse Drug Reaction (ADR): A response to a medicine in humans or animals, which 
is noxious and unintended, including lack of efficacy, and which occurs at any dosage 
and can also result from overdose, misuse or abuse of a medicine (MCC, 2014). 
Pharmacovigilance: The detection, assessment, understanding, management and 
prevention of adverse reactions to medicines (WHO, 2015). 
 
1. What is your profession?  
Doctor  
Registered Nurse  
Pharmacist  
         
2. What is your gender? 
Male  
Female  
         
3. How old are you? 
18 – 29 years old  
30 – 39 years old  
40 – 49 years old  
50 years or older  
         
4. For how many years have you been practicing? 
Less than 1 year  
1 – 5 years  
5 – 10 years  
Longer than 10 years  
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5. Have you ever received any pharmacovigilance or ADR reporting training?  
Yes  
No  
         
6. Have you ever seen the MCC ADR reporting form before? Please refer to the form 
attached on the last page.  
Yes  
No  
         
7. Do you know where to find the MCC ADR reporting form? Please refer to the form 
attached on the last page. 
Yes  
No  
 
8. How important do you think it is to report ADRs?  
Very important  
Important  
Not very important  
Not important at all  
         
9. Why do you think it might be important to report ADRs? Please rate each point on 
a scale from 1 to 5, with 1 being not important at all and 5 being very important. 
You can use the same number more than once.  
To identify new ADRs 1 2 3 4 5 
To share information about ADRs with colleagues 1 2 3 4 5 
To improve patient safety 1 2 3 4 5 
To help establish the safety of new drugs 1 2 3 4 5 
To measure the incidence or frequency of ADRs 1 2 3 4 5 
Because it is a legal requirement 1 2 3 4 5 
         
10. In your view, which ADRs should be reported?  
None  
All ADRs  
All serious ADRs (causing death or serious injury)  
ADRs to medical devices (such as pacemakers, prosthetics, etc)  
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ADRs to new drugs  
ADRs to herbal, natural or traditional medicines  
Other (please specify): 
         
11. Have you ever reported an ADR? 
Yes  
No  
         
12. Have you ever encountered an ADR and not reported it? 
Yes  
No  
I don’t know  
         
13. Please mark the statement(s) that apply to you regarding the process to follow 
when reporting an ADR: 
I know how to fill out an ADR form (see attached form)  
My line manager manages all ADR reports so I don’t really bother  
I don’t know the process to follow  
         
14. ADR reports are submitted to: 
Pharmacy Manager  
Nursing Manager  
Hospital Manager  
Head Office  
Medicines Control Council   
National Adverse Drug Event Monitoring Centre   
I don’t know  
         
15. When would you be most likely to report an ADR? 
It is a very serious ADR (causing death or serious injury)  
It is a very unusual reaction  
Somebody is watching me  
Certainty that it is an ADR  
A new or experimental drug is involved  
I would report all ADRs  
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16. What are the factors that might discourage you from reporting ADR’s? 
Do not know how to report  
Do not know where to report  
Did not think it was important to report  
Managing the patient was more important than reporting the ADR  
Lack of access to ADR reporting form  
Patient confidentiality might be breached  
Legal liability issues  
The form is too long  
I don’t receive any feedback once the form has been sent  
Other (please specify) 
         
17. In your opinion, which of these professionals should be responsible for reporting 
ADRs? 
Doctors  
Nurses  
Pharmacists  
Other (please specify) 
         
18. Do you think that your hospital submits sufficient and appropriate ADR reports? 
Yes  
No  
I don’t know  
         
19. Do you have any suggestions about how the culture of reporting can be 
improved? Please tick/cross the appropriate box(es). You can choose more than 
one option. 
ADR reporting made mandatory (i.e. will affect my monthly performance).  
Workshops and seminars.  
Pharmacovigilance teaching programmes for undergraduates, interns and postgraduates.  
Monthly meetings discussing common ADRs that may be encountered.  
Bring out bulletins on ADRs.  
Getting paid a sum of money for each ADR reported  
Other (please specify 
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20. Using a scale of 1 – 5, please indicate whether you agree or disagree with the 
following statements: 
1 – Strongly disagree                                              2 – Disagree 
3 – Neither agree nor disagree                               4 – Agree 
5 – Strongly agree 
ADR reporting is a professional obligation 1 2 3 4 5 
ADR reporting adds up to unnecessary workload 1 2 3 4 5 
Nobody really benefits if I report an ADR 1 2 3 4 5 
I would like to receive more training on ADR reporting 1 2 3 4 5 
 
 
Thank you for your co-operation!  
 
 
  
96 | P a g e  
 
APPENDIX B:  
      INFORMATION LEAFLET AND INFORMED CONSENT 
 
Study Number: M160238 
Study Title: An Evaluation of Health Care Worker Knowledge, Attitudes and Perceptions to 
Adverse Drug Reaction Reporting in the South African Private Sector 
Investigator: Ms Sophia Bogolubova 
Institution: University of the Witwatersrand 
24 Hr Contact Number: 072-212-6396 
 
To the potential participant:  
This information sheet and consent form may contain words that might need clarification. 
Please ask the investigator to explain any words or information that you do not clearly 
understand. You may take home an unsigned copy of this information sheet and 
consent form to think about or discuss with family or friends before making your 
decision. 
 
Good day,  
My name is Sophia Bogolubova, I am a pharmacist, and I am currently completing my 
Masters degree at the University of Witwatersrand. I would like to invite you to consider 
participating in a research study titled, “An Evaluation of Health Care Worker Knowledge, 
Attitudes and Perceptions to Adverse Drug Reaction Reporting in the South African Private 
Sector”. Before agreeing to participate, it is important to read and understand the following 
regarding the purpose of the study, the procedures, and your right to withdraw from the 
study at any time. This information leaflet will help you decide if you would like to participate. 
You should fully understand what is involved before you agree to take part in this study. You 
should not agree to take part unless you are satisfied about all the procedures involved. If 
you decide to take part in this study, you will be asked to sign an informed consent letter, 
which confirms that you understand the study and are participating voluntarily. 
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The purpose of the study is to gain an understanding of the knowledge, attitude and 
perceptions of doctors, registered nurses, and pharmacists within Life Healthcare with 
respect to ADR reporting.  
This study will be performed at Life Brenthurst Clinic, Life Flora Hospital, Life Fourways 
Hospital and Life Wilgeheuwel Hospital, and will have between 300 and 400 participants. 
Participants will include pharmacists, doctors and registered nurses that work at Life 
Healthcare. Each participant will be provided with a questionnaire composed of various 
multiple-choice questions. Should you wish to participate, you will have two weeks to 
complete the questionnaire and return it to either your Line Manager, or directly to the 
principle investigator. 
Your participation in this study is entirely voluntary and you can choose to decline to 
participate, or stop at any time, without stating any reason. Non-participation or withdrawal 
will not result in any disadvantage to you.  
This study has been approved by Human Research Ethics Committee (HREC) of the 
University of the Witwatersrand. In addition, this study protocol has been submitted to Life 
Healthcare Research and Scientific Committee for ethics clearance and approval. 
Should you have any questions, or require any further information, below are a list of the 
people that are involved with and working on this study.  
Name Role E-mail Tel 
Sophia 
Bogolubova 
Principle 
Investigator 
sophiebogolubov@gmail.com 072-212-6396 
Neelaveni 
Padayachee 
Supervisor Neelaveni.Padayachee@wits.ac.za (011) 717-2269 
Natalie 
Schellack 
Co-Supervisor Natalie.Shellack@smu.ac.za (012) 521-4312 
 
If you require any additional information regarding your rights as a research participant, or if 
you have any complaints regarding this study, you may contact the Chairperson of the 
Human Research Ethics Committee, University of the Witwatersrand: 
Prof. Cleaton Jones 011 717 2100 
 
All information obtained during the course of this study, including personal and research 
data, will be kept strictly confidential. You will not be required or asked to provide any 
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personal information, such as your name, address, ID number, employee number, telephone 
number, etc. Data may be reported in scientific journals, and will not include any information 
that might identify you as a participant in this study. This information might be inspected by 
the University of Witwatersrand, Human Research Ethics Committee (HREC), and Life 
Healthcare. This information will only be utilized by the abovementioned parties in connected 
with carrying out their obligations to this study.  
 
 
Thank you for taking the time to consider participating in my study. 
 
Sophia Bogolubova 
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APPENDIX C:  
INFORMED CONSENT 
• I hereby confirm that I have been informed by the principal investigator, Sophia 
Bogolubova, about the nature of the study (M160238, An Evaluation of Health Care 
Worker Knowledge, Attitudes and Perceptions to Adverse Drug Reaction Reporting 
in the South African Private Sector). 
• I have also received, read and understood the above written information (Information 
Leaflet and Informed Consent) regarding the study. 
• I am aware that the results of the study, including my profession and responses, will 
be anonymously processed into a study report. 
• In view of the requirements of research, I agree that the data collected during this 
study can be processed in a computerized system. 
• I may, at any stage, without prejudice, withdraw my consent and participation in the 
study. 
• I have had sufficient opportunity to ask questions and (of my own free will) declare 
myself prepared to participate in the study. 
 
PARTICIPANT: 
 
 
 
 
 
    
Printed Name  Signature  Date and Time  
 
PRINCIPLE INVESTIGATOR: 
I, Sophia Bogolubova, herewith confirm that the above participant has been fully informed 
about the nature of the above study. 
 
 
 
 
 
    
Printed Name  Signature  Date and Time  
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APPENDIX E:  
 
